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ABSTRACT

PARP1-Targeted Radiotherapies
by
Stephen Anthony Jannetti III

Advisors: Thomas Reiner & Brian M. Zeglis

Poly-ADP-ribosylation reactions were first reported by Chambon in 1963 as enzymatic
activity that increases incorporation of ATP in the presence of nicotinamide mononucleotide. In
the decades since that publication, Poly(ADP-ribose)polymerase 1 (PARP1) and the PARP family
enzymes have been widely studied. PARP enzymes are currently known to play various roles in
mammals, including anti-aging processes, interactions with Breast Cancer Suppressor Protein-1
(BRCA1), and DNA damage repair. A significant focus of PARP1 research has been elucidating
its role in DNA damage repair. PARP1 is recruited to repair single strand DNA (ssDNA) breaks,
which can become double stranded DNA (dsDNA) breaks if PARP1 is not present. It is now known
to be overexpressed in various cancers, as well as being linked to survival in gliomas.
The increased presence of PARP1 in cancer cells and the increased radio-sensitivity of the
cells when PARP1 is inhibited make it an exceptional target for therapies and imaging agents.
Naturally, several PARP inhibitors have since been developed and approved by the FDA. PARP1
expression in gliomas can be leveraged to design a radiotherapeutic that would be highly specific
for cancer cells while sparing surrounding healthy tissue in gliomas. Using one of these FDA
approved PARP inhibitors; several PARP imaging agents for fluorescent, PET, and SPECT
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modalities that retain specificity for PARP1 have been developed. The next step in the PARPi
imaging suite is to develop PARP-targeted radiotherapeutics and theranostics. A toolbox of
imaging and therapeutic agents with the same highly targeted specificity would provide a valuable
advantage when diagnosing patients, treating them, and even monitoring patient response or
disease progression.
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CHAPTER ONE – PARP Inhibitors and Radiation Therapy

The following chapter has been submitted to Frontiers in Pharmacology as a review.

Introduction
Poly(ADP-ribose)polymerase-1 (PARP1) is a 116 kDa DNA repair enzyme with nuclear
concentrations ranging from 2𝑥10% to 1𝑥10& enzymes/nucleus in eukaryotic cells (Herceg and
Wang 2001; Ludwig et al. 1988). Within 30 seconds of the advent of DNA damage, PARP
PARylates itself, activating the enzyme and leading to a 500-fold increase in its activity over basal
levels (Alvarez-Gonzalez and Althaus 1989; Benjamin and Gill 1980; Haince et al. 2008; Hassa
and Hottiger 2008; Langelier et al. 2012). If a cell’s DNA is not functionally repaired, PARP1 is
cleaved by a caspase, and the cell enters apoptosis (Kaufmann et al. 1993). Alternatively, a cell’s
energy pools can be depleted through the overactivation of PARP1, which will result in the cell
undergoing necrosis (Martin et al. 2000).
Over the past decade, inhibitors of PARP have emerged as a common monotherapy for
certain subtypes of breast and ovarian cancers (Tangutoori et al. 2015). Moreover, preclinical data
has demonstrated that PARP inhibition can increase radiosensitivity in cancer cells (Wang et al.
2019). The efficacy of combination therapies employing PARP inhibitors and external beam
radiation has been demonstrated in the clinic, and several phase I clinical trials based on this
approach have been completed at the time of writing (NCT00770471, NCT00649207,
NCT01264432, NCT01477489, NCT01514201, NCT01657799), with results being available for
some of them (Dréan et al. 2016; Russo et al. 2009; Tangutoori et al. 2015). The use of PARP
inhibitors as scaffolds for radiopharmaceuticals has also blossomed in recent years (Irwin et al.
2014; Salinas et al. 2015; Carney et al. 2016; Carney et al. 2017; Jannetti et al. 2018; Reilly et al.
1

2018; Pirovano et al. 2019; Makvandi et al. 2019). To wit, several clinical trials of PARP-inhibitorbased diagnostic imaging agents are currently in progress or have been completed
([18F]FluorThanatrace (Michel et al. 2017), PARPi-FL (Kossatz et al. 2019)), & [18F]PARPi
(Schoder et al. 2019)) and a number of therapeutic radiopharmaceuticals based on PARP inhibitors
have been employed in preclinical animal models (Kossatz et al. 2017b; Michel et al. 2017; Sander
Effron et al. 2017).

Mechanism of PARP Inhibition
DNA Binding
PARP1 is composed of six domains. Moving from the N-terminus to the C-terminus, the
enzyme contains three zinc fingers (Zn1, Zn2, Zn3), one domain for auto-poly(ADP-ribose)ylation
(autoPARylation domain; AD) that contains a breast cancer 1 protein (BRCT) motif on the cterminus of the domain, one domain that interacts with open chromatin (WGR) (Altmeyer et al.
2009; Thomas et al. 2019), and one domain associated with the enzyme’s catalytic activity (CAT)
comprised of a helical subdomain (HD) and a conserved ADP-ribosyl transferase subdomain
(ART). Zn1 and Zn2 are homologous domains that recognize and bind DNA, though it has been
shown that the enzyme can bind DNA with only one of these two domains (Langelier et al. 2011)
(Figure 1). Taken together, the Zn fingers engage not specific sequences of DNA but rather
structural motifs such as blunt ends, single strand breaks (SSBs), double strand breaks (DSBs), 3’
single-base overhangs, and long overhangs (D’Amours et al. 1999; D’Silva et al. 1999; Pion et al.
2003). It is important to note that in each of these cases, PARP1 binds to the irregular angle in the
broken DNA strand, not the exposed nucleotides (Lonskaya et al. 2005). Furthermore, each Zn

2

finger seems to play a particular role in a
different aspect of the enzyme’s function.
For example, Zn1 is responsible for binding
DSBs,

interacting

with

the

catalytic

domain, and activating PARP1. Zn2 seems
to be responsible for the recognition of
SSBs. (Eustermann et al. 2011). Zn3 has
been shown to play a critical role in proteinprotein

interactions

during

DNA-

dependent autoPARylation by initiating
Figure 1 – Schematic Representation And Crystal
Structure of PARP1. A. Schematic representation of
human PARP1 domains and subdomains. A BRCA
C-terminus (BRCT) fold is located within the region
of PARP1 that is primarily targeted for
automodification. The catatlyic domain is composed
of an alphahelical subdomain (HD) and an ADPribosyl transferase subdomain (ART). B. A model
for the approximate positioning of the Zn2 and
BRCT domains within the PARP1/DNA complex.
Zn1, Zn3, and WGR-CAT are shown as surfaces.
The Zn2 and BRCT domains are drawn in schematic
representation. Their positioning is based on the
relative location of the termini of adjacent domains
in the structure. The numbering and location of linker
residues are shown. The arrow indicates the location
of the PARP1 automodification region near the
catalytic active site. Figure adapted from Langelier
et al. 2012. (PDB code 4DQY, Langelier et al. 2012.)

hydrolysis

of

the

NAD+

substrate

(Langelier et al. 2008; Venere et al. 2014).
Unlike Zn1 and Zn2, Zn3 is not required for
DNA activation, though it does mediate
PARP1-chromatin interactions (Langelier
et al. 2010; Venere et al. 2014).

Single and Double Strand DNA Repair
The exact mechanism of DNA
repair by PARP1 is not entirely understood.

(Alemasova and Lavrik 2019). One proposed hypothesis is the homodimerization of PARP1 after
recruitment to the side of DNA damage to begin autoPARylation and the repair process (MendozaAlvarez and Alvarez-Gonzalez 1993; Bauer et al. 1986; Bauer et al. 1990; Mendoza-Alvarez and
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Alvarez-Gonzalez 1999; Mendoza-Alvarez and Alvarez-Gonzalez 2004). PARP1 has been shown
to dimerize in its active form in solution which, greatly increased its specific activity (pmol of
product/min per pmol of enzyme) (Bauer et al. 1990). PARP1 dimerization was also confirmed by
dynamic light scattering (Vasil’eva et al. 2019). The rate of automodification is a function of PARP
concentration consistent with second order kinetics. The rate kinetics suggest a dimerized model
in which two PARP1 enzymes initialize PARylation, each with an active NAD+ binding site
(Mendoza-Alvarez and Alvarez-Gonzalez 1993; Mendoza-Alvarez and Alvarez-Gonzalez 1999;
Mendoza-Alvarez and Alvarez-Gonzalez 2004). Interestingly, an earlier study supports a model
where optimal enzyme activity and PAR chain formation occur in a PARP1:DNA binding
stoichiometry of 2:1 where one PARP1 enzyme is catalytically active and the other PARP1 acts
as a receptor for PARylation (Panzeter and Althaus 1994). This model is supported by the crystal
structure of the Zn1 and Zn2 domains from separate PAPR1 enzymes in a dimer, complexing
damaged DNA (Ali et al. 2012). Another study found the 5’-recessed structure of DNA will recruit
PARP1 in a 2:1 PARP1:DNA stoichiometry (Pion et al. 2003). Once dimerized, PARylation and
autoPARylation are initiated. AutoPARylation takes place on glutamate and lysine residues found
in the AD (Altmeyer et al. 2009; Venere et al. 2014). This domain is also the site of protein-protein
interactions (WGR) with the downstream protein targets of PARP1 (Venere et al. 2014). However,
in the absence of an AD domain, PARP1 can still PARylate other proteins (Altmeyer et al. 2009).
There are several proteins which can be modified with potentially large, negatively charged
PAR chains, which have been found to be between 1 and 200 units long (Hakmé et al. 2008). It
has been suggested that as the length of the PAR chain increases the affinity of PARP1 for DNA
decreases, mostly due to its highly negative charge, allowing PARP1 to release the DNA and leave
space for other DNA repair proteins to bind (Ogata et al. 1980; Poirier et al. 1982; Timinszky et

4

al. 2009; Tulin and Spradling 2003). The PAR chain can be hydrolyzed to shorter PAR chains,
mono(ADP-ribose) by ADP-ribose hydrolase (ARH3) or PAR glycohydrolase (PARG) (Min and
Wang 2009; Oka et al. 2006). When ARH3 or PARG cleaves the first ADP-ribose in a PAR chain
from PARP it reestablishes the enzyme’s ability to recognize and bind DNA damage, essentially
“resetting” the PARP (Rouleau et al. 2010).
The most direct use of the PAR chain is as energy in the form of ATP when the cell is
experiencing decreased levels of ATP (Petermann 2003; Walker et al. 2006). It is known that DNA
damage leads to rapid depletion of ATP reserves in the cell (Sims et al. 1983). PARP is upregulated
when the cell’s demand of ATP is increased is to provide ATP from the PAR chain for LIG3 in
the BER pathway (Petermann 2003; Walker et al. 2006).
The PAR chain has been reported to have the potential to recruit an array of different
proteins (Rouleau et al. 2010). When interacting with acceptor proteins, the PAR chains can
modulate localization, function, and structure (Kraus 2008; Krishnakumar and Kraus 2010). Aside
from autoPARylation, target proteins for PARylation by PARP1 include other DNA repair
proteins, transcription factors, histones, and chromatin modulators (D’Amours et al. 1999; Hassa
and Hottiger 2008). One of the PARylation targets during DNA damage repair is H1, whose
targeting results in the relaxation of the chromatin super structure and recruitment of repair proteins
such as XRCC1 (El-Khamisy 2003; Okano et al. 2003). XRCC1 binds directly to the PAR chain,
whereas other repair proteins interact with mediating proteins that in turn bind PAR (Rouleau et
al. 2010).
Necessary, additional interactions between DNA repair proteins occur through a BRCA1
carboxy-terminal (BRCT) repeat motif found in many other proteins involved in DNA damage
repair (Kameshita et al. 1984). This domain, containing a conserved ADP binding sequence
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comprised of 20 amino acids, has been identified and found to overlap with domains in many
proteins associated with DNA binding, nuclear localization, nuclear export, protein degradation,
and protein-protein interaction (Pleschke et al. 2000). Two enzymes essential to homologous
recombination (HR), ataxia telangiectasia-mutated (ATM) and mitotic recombination 11 (MRE11)
are signaled through PAR as well (Haince et al. 2008; Sugimura et al. 2008).

Synthetic Lethality
Exploiting synthetic lethality ¾ a relationship between two cellular mechanisms wherein
the functional loss of one is survivable but the loss of both is lethal ¾ was proposed as a treatment
for cancer almost a quarter of a century ago (Hartwell et al. 1997). This strategy was validated
during the phase I trial of the PARP1/2 inhibitor olaparib, when the majority of patients with
BRCA1/2 mutations saw a benefit from PARPi intervention (Fong et al. 2009). In 2014, olaparib
received FDA approval for treatment of advanced ovarian cancer (Kim et al. 2015).
When the HR pathway is compromised, inhibition of the remaining PARP-dependent BER
pathway can be lethal to cells, although the exact mechanism is not entirely understood (Helleday
2011). Likely, the HR pathway fails in BRCA-deficient cells due to loss of function of BRCA1/2,
causing the cells to rely upon BER to repair damaged DNA (Ström et al. 2011). The BRCA1 and
BRCA2 genes code for the eponymous tumor-suppressing proteins essential to the HR repair
pathway (Roy et al. 2011). Loss of function of one of these genes via mutation is associated with
a high risk of breast and ovarian cancer (Miki et al. 1994; Wooster et al. 1995). These types of
BRCA1/2 negative cancers are naturally sensitive to PARP inhibitors (Bryant et al. 2005; Evers et
al. 2010; Farmer et al. 2005; Fong et al. 2009; Liu et al. 2008; Rottenberg et al. 2008).

6

Certain tumors arising from hereditary cancers that share an HR-deficient phenotype, not
just BRCA deficiency, are sometimes described by the term “BRCAness.” This includes any
mutation that would affect replication fork stability, or any genes involved in the HR pathway, for
example ATM, ATR, FANC, or PALB2 (Lord and Ashworth 2016; McCabe et al. 2006; Turner
et al. 2004). There is evidence of BRCAness and PARP inhibitors inducing synthetic lethality in
cancers that are known to have HR-deficient pathways, such as high-grade serous ovarian cancer
(HGS-OVCa), advanced prostate cancer, and pancreatic cancers (Bell et al. 2011; Carnevale and
Ashworth 2015; Lord and Ashworth 2016; Mateo et al. 2015; Waddell et al. 2015).
The first evidence of PARP inhibition inducing lethality appeared in the 1970’s when
NAD+ analogs were used to bind PARP1 in combination with a genotoxic agent (Brightwell et al.
1975; Purnell and Whish 1980; Terada et al. 1979). At the time of writing, four therapeutic PARP
inhibitors have been approved by the FDA (olaparib, rucaparib, niraparib, and talazoparib) and
four more are in various stages of clinical trials (veliparib, E7016, CEP-9722, BGB-290;
NCT01827384, NCT01605162, NCT01345357, NCT03150810, respectively).

PARP Trapping
PARP trapping is the formation of a PARP-DNA complex through inhibition of DNAbound PARP. PARP-DNA complexes were detected in cell lines treated with olaparib and
rucaparib (Murai et al. 2012; Murai et al. 2014). PARP inhibitors prevent PARP from synthesizing
PAR chains by competitively binding PARP’s natural substrate, NAD+.
Interestingly, inhibiting PARP is more cytotoxic than the absence of PARP itself (Thomas
et al. 2018). One hypothesis for this effect might be due to replication fork stalling and subsequent
collapse, a mechanism shared with topoisomerase I (TOP1) and TOP1 inhibitors. Further evidence
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of PARP trapping and collapsing replication forks is PARP1’s role in restarting stalled replication
forks, a task prevented by PARP inhibitors (Bryant et al. 2009; Yang et al. 2004). This mechanism
sheds some light on the lethality of PARP inhibitors in cells with and without BRCA mutations
(Strumberg et al. 2000).
The efficacy of PARP trapping was shown to be independent of the half-maximal
inhibitory concentration (IC50) of the PARP inhibitors (Murai et al. 2012; Murai et al. 2014). Of
the FDA-approved PARP inhibitors, veliparib is the least effective at PARP trapping, irrespective
of the fact that its IC50 value is lower than that of niraparib (2 nM and 3.2 nM, respectively).
Olaparib has a higher IC50 than rucaparib (5 nM and 1.4 nM for olaparib and rucaparib,
respectively), and they exhibit equal efficacy as PARP trapping agents. Talazoparib has the lowest
IC50, 0.57 nM, and functions as the best PARP trapping agent (Murai et al. 2012). Talazoparib’s
ability to trap PARP is likely due to its bulky structure and rigidly which contributes to a slow offrate (Pommier et al. 2016). Recent combination trials have demonstrated new indications of PARP
inhibitors in combination with other therapeutics, extending their use beyond cancers with
BRCAness. One such example includes a combination therapy of rucaparib and temozolomide, an
alkylating agent used as the standard of care in glioblastoma, in metastatic melanoma, a cancer not
typically associated with BRCA1/2 mutations (Plummer et al. 2013).

PARP Inhibition as a Radiosensitizer
While synthetic lethality via PARP inhibitors is frequently associated with BRCA1/2
mutations in the literature, many genes play crucial roles in various stages of the HR repair
pathway (Cejka 2015; Hoa et al. 2015). An example of how PARP inhibitors can be lethal to HRdeficient cells is their effect on XRCC1-deficient cells. An increased amount of SSBs were
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detected when XRCC1-deficient cells were treated with a PARP inhibitor (Ström et al. 2011). If
the HR pathway is disabled, synthetic lethality can be induced with PARP inhibitors in
combination with inhibitors of certain proteins signaled by PARP. Experimental results suggest
HR-proficient cell lines can be sensitized to PARP inhibitors through inhibition of the BET
proteins (Yang et al. 2017). BRCA-proficient ovarian cancer cells treated with a BET inhibitor
accumulated more DNA damage after being treated with olaparib. A mouse xenograft model
treated with a combination of these inhibitors lead to significant tumor growth delay (Karakashev
et al. 2017). Inhibition of BRD4 protein induces HR deficiency in multiple cancer cell lines and
can even re-sensitize cells that have acquired resistance to PARP inhibitors (Sun et al. 2018).

Increased Genomic Instability After PARP Inhibition
Originally, the mechanism proposed for PARP-inhibitor-mediated synthetic lethality was
the accumulation of DSBs produced when a replication fork failed after encountering an inhibited
PARP bound to an SSB (Farmer et al. 2005). There is evidence that cells undergoing PARP
inhibition contain no significant increase in SSBs (Gottipati et al. 2010; Ström et al. 2011). PARP
knockout cells and PARP knockdown cells contain no higher level of SSBs than wildtype cells
(Fisher et al. 2007). These findings suggest alternate explanation of PARP inhibitor-mediated
synthetic lethality.
PARP more directly affects the genome through PARylating histones and other nuclear
proteins to unwind the chromatin structure (Althaus et al. 1994; De Murcia et al. 1986). An
increased level of biomarkers of genomic instability, such as DNA strand breaks, gene
amplification, DNA recombination, and SSB were found in cells with decreased PARP activity
after treatment with DNA-damaging agents. These findings were made using PARP inhibitors,
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PARP knockout models, and asRNA models (Ding and Smulson 1994; Küpper et al. 1990;
Schreiber et al. 1995; Waldman and Waldman 1991).
These results lead to the hypothesis that when HR and BER pathways are inaccessible to
cells, they rely on non-homologous end joining (NHEJ). HR and BER are conservative DNA repair
methods, maintaining the original DNA sequence that was damaged. When HR is not an option
for the cell, it has to rely on BER and NHEJ. NHEJ is a non-conservative repair pathway, because
it will excise the damaged DNA, leading to genomic instability (Moynahan et al. 2001; Tutt et al.
2001). It has been shown that NHEJ is promoted in cells with defective HR pathways after
treatment of PARP inhibitors. Also, resistance to PARP inhibitors is acquired when the NHEJ
pathway is inhibited (Patel et al. 2011). These findings indicate that PARP-inhibitor-induced
lethality can also be attributed to genomic instability as a result of the NHEJ pathway.

Preclinical Models of Combination Therapies
In Vitro – Clonogenic Assays
The Marples group out of Wayne State University has demonstrated that radiosensitivity
can be increased through PARP inhibition in human glioma cell lines U373-MG and T98G.
Clonogenicity was evaluated with increasing concentrations of PARP inhibitors (1-3 μM) that
were found to be non-toxic in the absence of radiation. A 3 μM concentration of PARP inhibitor,
the highest concentration of inhibitor that was non-toxic in the absence of ionizing radiation (IR),
was then used in conjunction with low levels (0.05-0.3 Gy) of ionizing radiation to induce toxicity
(Chalmers et al. 2004). Treatment with a small molecule PARP inhibitor, AG14361, followed by
8 Gy IR reduced survivability in colorectal cancer cell lines (LoVo) by 73% (Calabrese et al. 2004).
Non-small cell lung cancer (NSCLC) cell lines A549 and Calu-6 were each treated with 1 μM and
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5 μM of olaparib before being exposed to 0, 2, 4, 6 Gy to find dose-dependent sensitization of both
cell lines. For A549 and Calu-6 the Survival Enhancement Ratio (SER) values after treatment with
1 μM of olaparib were found to be 1.3 and 1.5, respectively. These ratios increased to 1.6 and 1.8
after treatment of 5 μM olaparib, indicating a survival benefit when olaparib is combined with IR
(Senra et al. 2011). Veliparib was shown to have a limit on radiosensitization with concentrations
above 2.5 μM no longer increasing radiosensitivity in a NSCLC cell line, H1299. Survival
fractions were decreased when IR was supplemented by pretreatment of 2.5 μM veliparib. This
effect was also observed in human prostate cancer cell lines (DU145 and 22Rv1) (Liu et al. 2008).
The PARP inhibitor E7016 was able to increase radiosensitivity across multiple cancer cell lines
as well. A dose enhance factor ≥ 1.4 was calculated for glioblastoma (U251) and pancreatic
(MiaPaCa), and prostate cancer (DU145) cell lines when treated with E7016 prior to IR. Surviving
fractions in all three cell lines were reduced to 0.1 in clonogenic assays (Russo et al. 2009).
Veliparib demonstrated no effect on colony formation in PC-3 prostate cancer cells when
incubated in 10 μM veliparib. The same treatment, followed by 2 Gy IR, reduced colony formation
to 47% (Barreto-Andrade et al. 2011). 22Rv1 prostate cancer cells had PARylation reduced by 97100% after incubation with the PARP inhibitor olaparib. The radiosensitization enhancement ratio
was found to be ≥ 1.2 when combined with IR compared to PARP inhibitor alone. This result was
found in acutely hypoxic, chronically hypoxic, and normoxic conditions (Gani et al. 2015). These
works establish the efficacy of a variety of PARP inhibitors as radiosensitizers for multiple human
cancer cell lines at low μM concentrations, often below cytotoxic concentrations of the PARP
inhibitors themselves.
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In Vivo – Tumor Growth Delay & Survival
Combination therapy is a more efficacious approach to treating H460 models of non-small
cell lung cancer. A tumor growth delay assay using a five-fold increase in tumor volume as an
endpoint saw a 1-day or 7-day delay using the PARP inhibitor veliparib or external beam radiation
alone, respectively. When these therapies were combined, the five-fold increase in tumor volume
was delayed by 13.5 days (Albert et al. 2007). A subcutaneous LoVo xenograft model of colorectal
cancer exhibited tumor growth delay of 19 days with a fractionated regimen of IR that was
increased to 37 days when combined with a low dose of AG14361, which did not delay tumor
growth when administered alone (Calabrese et al. 2004). Tumor growth was significantly impeded
in a dose-dependent trend of GPI-15427 and 2 Gy in mouse models of JHU006 and JHU012
HNSCC (Khan et al. 2009). A dose response dependency of veliparib was demonstrated in a
human colon cancer mouse xenograft model, HCT116, when administered through a
subcutaneously implanted osmotic pump in conjunction with IR compared to IR alone (Donawho
et al. 2007). Calu-6 mouse xenograft models received a daily 50 mg/kg dose of olaparib for 5 days,
5 days of 2 Gy IR daily, or both therapies. The combination therapy cohort experienced a
significant delay of 10 days to reach the endpoint compared to either monotherapy or control
cohort (Senra et al. 2011).
Mouse models of HCT116 colorectal cancer receiving twice daily orally administered
doses of 12.5 mg/kg of veliparib in conjunction with 2 Gy fractions of IR displayed significant
tumor growth delay compared to control groups of IR alone (Shelton et al. 2013). Olaparib was
also tested as a radiosensitizer in subcutaneous mouse models of glioblastoma-initiating cells.
Daily treatment of olaparib over seven days was administered concurrently with 3 Gy of IR every
other day for three total doses to find greater tumor growth delay than vehicle, IR alone, or IR with
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vehicle (Venere et al. 2014). The effect of fractionated RT after sensitization by olaparib was
evaluated in a 22Rv1 human prostate cancer mouse model. One cohort received a single 8 Gy dose
on the third day of 3 consecutive daily doses of intraperitoneally administered PARP inhibitor. A
second cohort was treated with 7 consecutive days of olaparib, with 5 x 2 Gy doses every other
day starting 3 days after the initial PARP inhibitor injection. The group receiving fractionated
doses displaying a non-significant delay in tumor growth compared to the vehicle + fractionated
IR control group (Gani et al. 2015). The above data suggests that a combination therapy between
PARP inhibitors and RT is more effective in vitro and in vivo than either therapy alone.

Combination Therapy Clinical Trials
Ionizing Radiation with Chemotherapy and PARPis
There are currently several completed clinical trials exploring the efficacy of combining
PARP inhibitors, radiotherapy and chemotherapy, none of which have available results. In a phase
I study of patients with phase II or III rectal cancer, patients were given 825 mg/m2 capecitabine
twice daily and 1.8 Gy fractions daily for a total of 50.4 Gy over approximately 6 weeks in
conjunction with escalating doses (20-400 mg) of veliparib orally twice daily. Maximum tolerated
dose was not reached, and the study found 400 mg twice daily to be the appropriate dose of
veliparib for the phase II study (NCT01589419, (Czito et al. 2017). Two other phase I studies
evaluating the combination of veliparib and temozolomide against diffuse pontine glioma and
glioblastoma have also concluded, but results have not yet been posted (NCT01514201,
NCT00770471)
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Ionizing Radiation with PARPis
The first clinical trial exploring combination therapy between PARP inhibitors and ionizing
radiation to publish results combines veliparib and whole brain radiation therapy (WBRT) in adult
patients with brain metastases from non-small cell lung cancer (NCT00649207). Patients were age
> 18 years with Karnofsky performance status (KPS) scores ≥ 70. One arm received whole brain
radiation therapy (WBRT) administered daily in 2.5 Gy fractions over 15 sessions for 37.5 Gy
total. A second arm was treated with 150 mg of veliparib twice daily with concurrent daily
fractions of 3.0 Gy fractions over two weeks for 30 Gy.
All three arms of the study received a 30 Gy fractionated dose of 10 x 3 Gy doses,
excluding weekends and holidays. The variable was the quantity of drug received twice daily:
placebo, 50 mg veliparib, or 200 mg veliparib. The primary outcome was survival up to 36 months.
While the patient tumor population was homogenous, 88-90% of patients in this trial had Graded
Prognosis Assessment scores ≤ 2.5, amounting to an unfavorable prognosis, and the primary
outcome was not met (Chabot et al. 2017). It is worth noting that even when a combination therapy
significantly prolongs survival in patient populations with favorable prognoses (GPA 2.5-4), it
falls short of significance in populations with unfavorable prognoses (Aoyama et al. 2015). This
study progressed to phase II (NCT01657799), where no benefit was found in combining WBRT
with veliparib compared to WBRT and a placebo (Chabot et al. 2017).
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New Frontiers – PARPi Diagnostics & Radiotherapies
PARPi-FL
PARPi-FL was first reported in 2012 by the Weissleder Lab at Massachusetts General
Hospital in human pancreatic cancer cells (Reiner et al. 2012). It can be used for real-time
visualization of intracellular kinetics of PARP inhibitors (Thurber et al. 2013). It was later shown
to be a viable imaging agent in vivo in a mouse model of glioblastoma (Irwin et al. 2014).
Composed of a BODIPY-FL dye conjugated to an olaparib scaffold, it retains a similar
pharmacokinetic profile, including the low IC50 value of 12.2 nM compared to the 5.0 nM value
of olaparib (Menear et al. 2008). It can also be blocked by pretreatment with olaparib. PARPi-FL
uptake in tumors is rapid, with statistically significantly increased tumor-to-muscle and tumor-tobrain ratios of ≥ 10 in a mouse model of glioblastoma. Uptake of PARPi-FL was correlated to
PARP1 expression, and increased after irradiation (Irwin et al. 2014; Kossatz et al. 2017b).
Retention persists for hours, with < 50% metabolites present in the blood at peak uptake in tumors
(Irwin et al. 2014). PARPi-FL has been used for real-time measurements of drug-target interaction
in vitro and in vivo (Dubach et al. 2014; Dubach et al. 2017). The translational potential of PARPiFL was highlighted when high tumor-to-organ ratios were observed in an orthotopic model of oral
squamous cell carcinoma using clinical imaging instruments (Carney et al. 2017; Kossatz et al.
2017b), and early clinical outcomes have been reported (NCT03085147 and (Kossatz et al. 2019)).

PARPi-derived PET Tracers
The first radiolabeled PARP inhibitor for PET imaging was designed to monitor tissue
necrosis. The Mach Group at Washington University labeled the small molecule PARP1 inhibitor
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PJ34 with carbon-11 and had good yields with increased uptake in target tissue in a rat model of
Type I diabetes (Tu et al. 2005). The first reported fluorine-18-labeled PARP inhibitor was
[18F]FE-LS-75 from the Roesch Group at Johannes Gutenberg-University, which showed high
yields up to 80% (Riss et al. 2009) but did not report in vitro/vivo experiments. The first fluorinated
PARP-targeted small molecule based on a later FDA-approved PARP inhibitor was

18

F-BO

(Keliher et al. 2011). Uptake was shown to correlate to PARP1 expression in breast cancer mouse
models. A dose of olaparib prior to injection with

18

F-BO was able to reduce uptake in vivo.

Favorable uptake was also observed in pancreatic and ovarian cancer models (Reiner et al. 2012)
(Figure 2A, B).
developed

as

18

a

F-PARPi-FL was
dual

modality

PET/fluorescent imaging agent (Keliher
et al. 2014). PARP1-specific uptake was
demonstrated

in

glioblastoma

xenografts. Both modalities showed
similar tumor-to-brain uptake ratios
(PET,

9:1;

fluorescence,

7:1)

as

determined by autoradiography and
fluorescence microscopy (Carlucci et al. Figure 2 – In Vivo PET/CT Imaging. A. Correlation of
18
F-BO uptake and PARP expression in two ovarian
18
and
two pancreatic tumor types as determined by
2015). F-PARPi is an olaparib-based
immunoblotting. B. Coronal and axial PET/CT scans of
PET imaging agent that exhibits high a subcutaneous A2780 tumor-bearing mouse. (Reiner et
al. 2012). C. Sagittal PET/CT images of orthotopic
specificity for PARP1 in mouse models U251 MG tumor-bearing mice 2 h post-injection of 18FPARPi. D. PET/CT 2 h post-injection 18F-PARPi after
of orthotopic glioblastoma, diffuse 30 m pre-injection of 500-fold excess olaparib. (Carney
et al. 2015) E. MicroPET images of MDA-MB-231
intrinsic pontine glioma, and small-cell tumors in mice tumor at 60 min after 18F-FTT injection
before and after treatment with olaparib (ip 50 mg/kg
20 min pretreatment (Zhou et al. 2014).
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lung cancer (Carney et al. 2016; Carney et al. 2018; Kossatz et al. 2017a) (Figure 2C, D).
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F-

PARPi has potential to non-invasively monitor disease progression and is currently in phase I
clinical trials ((Schoder et al. 2019), NCT03631017). Wilson et al. has published the synthesis and
in vivo biodistribution of a fluorine-18 isotopologue of olaparib. Pre-irradiation of the cells and
tumors was shown to increase uptake of the compound in several pancreatic cancer cell lines
(Wilson et al. 2019). 18F-FluorThanatrace (18F-FTT) is a rucaparib-based PET imaging agent first
published in a human breast cancer mode (Zhou et al. 2014) (Figure 2E). It was the first PARPtargeted PET imaging agent to be tested in the clinic and is currently involved in several phase I
clinical trials, evaluating uptake in different cancers (Michel et al. 2017)

PARPi Radiotherapeutics
Several PARP inhibitors have also been labeled with therapeutic isotopes (Jannetti et al.
2018; Makvandi et al. 2019; Pirovano et al. 2019; Reilly et al. 2018; Salinas et al. 2015). The
pharmacokinetic profiles of several iodinated PARP inhibitors based on olaparib were explored in
human glioblastoma models in vitro and in vivo. Various length linkers were evaluated using an
olaparib scaffold and a small library of iodobenzoic acids. The compounds with the best
pharmacokinetics were radioiodinated and evaluated in culture and orthotopic mouse models of
human glioblastoma for PARP1 specificity (Salinas et al. 2015).The rucaparib scaffold was also
leveraged in the design and synthesis of alpha- and auger-emitting radiotherapeutics using coppercatalyzed halogenation of boronic esters (Makvandi et al. 2019; Reilly et al. 2018). The efficacy
of PARP-targeted radiotherapeutics was first published in subcutaneous mouse models of
glioblastoma, and later in orthotopic models of human glioblastoma (Jannetti et al. 2018; Pirovano
et al. 2019). Intratumoral injections were implemented to mimic Convection Enhanced Delivery
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(CED) an approach that elevates the injection pressure so as to impel the agent across the BBB. A
reporter cell line transduced from U87 cells was designed to respond to p53 activation, as well as
cellular density. This allowed imaging of cell death following treatment with the iodinated PARP
inhibitor. Therapeutic efficacy was evaluated in a tumor growth delay experiment that found a
fractionated dose of the drug could significantly delay the endpoint of the study (Figure 3A). Use
of a CED-mimicking subcutaneous implant allowed approximately 9 Gy to be delivered to a braintumor-bearing mouse compared to 1 Gy in a healthy mouse (Jannetti et al. 2018) (Figure 3B, C).
These results were leveraged in the synthesis and validation of an Auger-electron emitting
isotopologue. Uptake of the drug can be decreased by pretreatment with olaparib and proved lethal
to cells at concentrations lower than that of olaparib (EC50 = 69 nM). The radiotheranostic proved
efficacious in prolonging survival of treated mice, and intratumoral administration of the drug in
mice bearing human brain tumor significantly increased survival compared to vehicle alone (p =
0.0094). Application of CED-mimicking implants replicated this effect in the same model (p =
0.0361, (Pirovano et al. 2019)) (Figure 3D, E). High radiochemical yields (≥ 89%) were reported
for halogenation of both olaparib and rucaparib scaffolds with astatine-211 and iodine-125 (Reilly
et al. 2018). Antitumor effects were observed using an astatinated PARP inhibitor in a mouse
model of neuroblastoma. Favorable uptake was observed in the tumor after 2 hours. A single dose
of the alpha-emitting drug was able to significantly delay tumor growth and prolong survival
against a control group (Makvandi et al. 2019) (Figure 3F, G).
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Figure 3 – PARP Targeted Radiotherapies. A. Survival plot and table of treatment groups
with median survival of subcutaneous U87-p53 tumor-bearing mice. P = 0.0001. B.
SPECT/CT of orthotopic U87-p53 tumors during osmotic pump treatment of 131I-PARPi at
72 hours. C. Calculated absorbed dose to brain* during treatment. *Brain and tumor have
been considered together as a single organ in organ level dose calculation. (Jannetti et al.
2018). D. Dosimetry of the subcutaneous pump model showing CT, phantom and Monte
Carlo simulation of dose accumulation in the tumor. E. Kaplan-Meier survival study of
pump implanted mice shows an improvement of survival of 123I-MAPi treated mice (n = 8)
when compared to control (n = 8). *p-value < 0.05 (Pirovano et al. 2019). F. Tumor growth
and Kaplan–Meier curves for IMR-05 tumor–bearing mice Treated with single dose of 555
or 1,110 kBq of [211At]MM4 (control vs. 555 kBq and 1,110 kBqmixed linear model P <
0.0001; control vs. 555 and 1,110 kBq survival Mantel–Cox test P < 0.0001, 555 vs. 1,110
kBq not significant;, G. and single high dose of 1,480 kBq versus a fractionated dose of 370
kBq twice weekly for a cumulative dose of 1,480 kBq (control vs. fractionated mixed linear
model P < 0.0001, fractionated vs. high dose not significant; survival Mantel–Cox test high
dose vs. control P < 0.0001, fractionated vs. control P < 0.03. (Makvandi et al. 2019).
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CHAPTER TWO - Beta-Particle Radiotherapy in Mouse Models of Glioblastoma

The following chapter was reproduced from publication “Targeted Radiotherapy in Mouse
Models of Glioblastoma” by Jannetti et al. 2018 in the Journal of Nuclear Medicine. (Jannetti
et al. 2018).

Introduction
Glioblastoma is the most common primary brain tumor in adults, with more than
12,000 diagnoses per year (Alexander and Cloughesy 2017). Current standard treatment
consists of maximal surgical resection followed by chemotherapy (temozolomide) and
external beam radiation. This, however, only minimally extends median survival (Bi and
Beroukhim 2014), and most patients develop recurrent tumors within months (Holland 2000;
Park et al. 2010). The diffuse growth pattern is the fundamental reason why surgical resection
and external beam radiotherapy are insufficient, because highly dispersed glioblastoma cells
would require larger tumor margins to be treated and resected, which can result in
unacceptably high healthy tissue loss and significant morbidities. A selective cellular-based
approach would provide significant advantages over conventional therapy.
Recently, progress has been made toward the delivery of targeted therapeutics to
central nervous system tumors, especially using convection enhanced delivery (CED) (Anjum
et al. 2017; Vogelbaum and Aghi 2015). This strategy uses catheters to infuse therapeutics
directly into the affected brain tissue, where they are distributed by convective rather than
diffusive properties. This approach offers considerable advantages for delivery and tissue
penetrance of therapeutic antibodies, virus vectors, and cell-based therapeutics. Using this
technology, even radiolabeled antibodies, which normally have limited tissue penetration, can
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be delivered (Luther et al. 2014), potentially improving therapeutic efficacy. Nevertheless,
because of the heterogeneous nature of the disease (Parker et al. 2015), further enhancement
of delivery and tissue penetration is necessary, which could be achieved through CED of
targeted small-molecule radiotherapeutics.
One target for use in CED and targeted radiation therapy is poly (ADP-ribose)
polymerase (PARP1). PARP1 is a fundamentally important member of the cellular DNA
repair machinery that highly proliferative cancer cells rely on to maintain genomic integrity
through an accelerated cell cycle (Pommier et al. 2016). PARP1 expression was reported in the
nucleoli of neurons, oligodentritic cells, and astrocytes as well as the Purkinje cell layer in the
cerebellum and the dentate gyrus (Kossatz et al. 2017a). Nevertheless, it has been shown that
malignant glial growths have elevated PARP1 expression compared with healthy pediatric
and adult brain tissue (Murnyák et al. 2017), forming an ideal foundation for CED-based
therapeutics. Similarly, important, PARP inhibitors not only quickly distribute and bind
within PARP-expressing cells, but also simultaneously washout effectively from healthy
tissues, resulting in high target-to-background contrast (Carney et al. 2017; Kossatz et al.
2017a), potentially providing a large treatment window for CED therapy (Luther et al. 2014).
Recently, advances have been made in PARP-targeted molecular imaging, and much of this
work has focused on glioblastoma (Carlucci et al. 2015; Salinas et al. 2015) and other central
nervous system tumors (Kossatz et al. 2017a). Intuitively, replacing a fluorescent or PET active
imaging tag with a radiotherapeutic isotope would take advantage of the high specificity
exhibited by the PARP-targeted imaging agents as well as the high PARP expression seen in
glioblastoma. More information on the relevant chemistry and PARP inhibitors used for
imaging are provided in comprehensive reviews (Carney et al. 2017; Knight et al. 2017).
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In this study, we use 131I-PARPi, a small-molecule derived from an inhibitor screening
library (Salinas et al. 2015) and explore and develop its value as a CED agent for glioblastoma
therapy. We found that the binding profile of

131

I-PARPi matches that of other PARP

inhibitors and imaging agents. In a mouse model of glioblastoma, we investigate the
pharmacokinetics of 131I-PARPi and estimate the delivered radiotherapeutic doses. We show
that p53 expression was activated by

131

I-PARPi and that both single and fractionated doses

extend the overall survival of tumor-bearing mice. In an orthotopic model of glioblastoma,
we corroborate that high levels of

131

I-PARPi accumulate via CED, whereas healthy brain

tissue only retains the small molecule at low levels. Taken together, our results show that 131IPARPi is a promising radiotherapeutic small molecule and could potentially improve
glioblastoma therapy.

Results
Synthesis, Specificity, and In Vitro Performance of 131I-PARPi
Several research groups have synthesized PARP-targeted radiotracers in the past; some of
which were attached to radioiodine (Anderson et al. 2016; Makvandi et al. 2016; Salinas et al.
2015; Zmuda et al. 2015). We showed that one of these tracers, 131I-PARPi (Salinas et al. 2015),
has a high affinity with a concentration at which 50% of binding has been inhibited (IC50) in the
nanomolar range (11 ± 3 nM) and a logPCHI of 2.3. 131I-PARPi was synthesized with a final molar
activity of 1.5 GBq/µmol. Radiochemical purity was 99.1% ± 0.9% for all prepared compounds.
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131

Pharmacologically,

I-PARPi

behaves in a manner similar to the
Food and Drug Administration–
approved PARP inhibitor olaparib
(Figure 4, 5; (Menear et al. 2008)).
We tested the inhibitory
activity of 127I-PARPi on a panel of

Figure 4 – 131I-PARPi and Binding. A. In vitro studies of
131
I-PARPi (Salinas et al.
12 PARP enzymes, including PARP inhibitors. Structure of
2015). B. Heat map of binding characteristics of synthetic
tankyrase 1 and tankyrase 2 (Figure inhibitors (at 100 nM) to PARP family enzymes131in
percentage enzyme inhibition. C. Cellular uptake of I4B). We found near-perfect overlap PARPi alone and blocked with mass excess dose of olaparib.
with literature-known values for

18

F-PARPi, PARPi-FL, and olaparib at 100 nM (Carney et al.

2017). 18F-PARPi is a PARP-targeted PET imaging agent with an IC50 of 3 nM (Figure 5) (Carney
et al. 2016). PARPi-FL is a fluorescent PARP inhibitor with an IC50 value of 12.2 ± 1.1 (17). The
2 dominant targets for

127

I-PARPi were found to be PARP1 and PARP2, just as for 18F-PARPi,

PARPi-FL, and olaparib (Carney et al. 2018).
The in vitro binding specificity and internalization of 131I-PARPi was shown by incubating
U251-MG cells with

131

I-PARPi in the presence and absence of 150 µL of 6.67 µg/µL olaparib

solution suspended in 25 µL of DMSO, 25 µL of polyethylene glycol (PEG), and 100 µL saline
(Figure 4C). In both cases, binding reached a plateau at approximately 50 min and was 10-fold
higher in cells exposed to only 131I-PARPi than in cells co-incubated with olaparib. Additionally,
we showed that the radiotherapeutic binds to its intended target within the nucleus by incubating
U251-MG cells with serial dilutions of its nonradioactive counterpart, 127I-PARPi, in the presence
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Figure 5 – Chemical Structures of PARP inhibitors. A. Olaparib B. 18F-PARPi
of 0.5 µM PARPi-FL. Overall, uptake of PARPi-FL retained in the nucleus at a concentration of
0.5 µM could be suppressed by addition of a 20-fold excess of 127I-PARPi (Figure 6).

Intratumoral Injection and Tissue Perfusion of 131I-PARPi
Intratumoral injections were implemented with a clinical CED model in mind, as well as
for the favorable biodistribution (Figure 7). To determine how intratumorally injected

131

I-

PARPi/127I-PARPi distributes throughout a tumor, we designed an in vivo competitive binding
specificity experiment with

18

F-PARPi, a previously described PET imaging agent for PARP1.

One cohort of animals was intratumorally injected with
min later. The second cohort was injected with
intratumoral injection of
molecule occupies

18

127

18

127

I-PARPi, followed by

18

F-PARPi 30

F-PARPi only (Figure 7A). We found that

I-PARPi suppressed uptake of

18

F-PARPi, indicating that the small

F-PARPi binding sites (Figure 7B, C), similar to what we showed in

18

F-

PARPi/olaparib blocking experiments previously (Carney et al. 2016). Ex vivo quantification at 1
h after injection of 18F-PARPi demonstrated that uptake dropped by 1.7 ± 0.1 %ID/g (1.9 ± 0.3
and 0.18 ± 0.07 %ID/g, P < 0.0001) between mice without and with intratumoral injection of 127IPARPi (Figure 7C). When replicated with olaparib and 131I-PARPi, brain uptake was low between
mice without and with intravenous injection of olaparib (0.056 ± 0.020 and 0.061 ± 0.026 %ID/g,
respectively) (Figures 8, 9). Using autoradiography, we found heterogeneity in the intratumoral
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distribution of
131

I-PARPi

(Figure

10).

Overall
quantification,
however,
corroborated
the

18

F-PARPi

PET
experiments

Figure 6 – In Vitro Studies of PARP Inhibitors. A. Indirect measurement of
127
I-PARPi uptake into U251 cells via fluorescence microscopy of PARPi-FL
uptake following incubation with 0, 50, or 500 nM 127I-PARPi. Nuclei were costained with Hoechst DNA stain. B. Quantification of PARPi- FL uptake into
U251 cells following incubation with 0, 50, or 100 nM 127I-PARPi from
fluorescence microscopy data.

(Figure 7), and ratios between animals receiving only

131

I-PARPi versus animals receiving a

preinjection of olaparib were 7.8 (144.3 ± 32.7 AU and 18.5 ± 1.2 AU, P < 0.0001 for mice
without and with preinjection of olaparib) (Figure 10).

131

I-PARPi Pharmacokinetics and Dosimetry in Glioblastoma
CED delivery of therapeutics to the brain relies on a drug’s fast perfusion, tissue

permeability, and clearance from areas not expressing the targeted biomarker. To simulate this
setting, we tested retention of 131I-PARPi in 2 cohorts of U251-MG subcutaneous xenografts. In 1
cohort, PARP was made unable to retain the radiotherapeutic through intravenous pre-injection of
olaparib. NanoSPECT/CT showed that at 6 h after intratumoral injection of 131I-PARPi (11.1 MBq,
20 µL, 30% PEG/0.9% NaCl solution), the radiotherapeutic was retained in tumors not previously
injected with olaparib, whereas it had almost completely cleared from the blocked group (Figure
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11A). This observation was further corroborated
by biodistribution experiments with endpoints
(each time point n = 4) between 0 and 96 h after
injection (Figures 11B, C; Figures 8, 9, 12). On
the basis of these data, we calculated the activity
and dose retained in different tissues (Figure 13).
Intuitively, the highest dose was delivered to
tumor tissue, with a calculated absorbed dose of
134.1 cGy/MBq. This was followed by the thyroid
(68.6 cGy/MBq), which metabolizes and stores
iodine (Figure 12; (Bianco and Kim 2006)).
Besides PARP expression in the thyroid, storage
of metabolized iodine is likely one reason for this
comparatively high calculated dose. This is
supported by the finding that in this setting,
physical decay was observed as the only mode of
clearance. However, moving forward, thyroid
uptake

can

efficiently

be

blocked

by

administration of nonradioactive iodide (Brans et
al. 2002).
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Figure 7 – 131I-PARPi Binding Specificity. A.
Experimental outline of immuno-PET/CT
imaging after injection of nonradioactive
version of 131I-PARPi (127I-PARPi). B. 18FPARPi PET tracer injected intravenously 30
min before intratumoral injection of 127IPARPi. PET scan of mice 2 h after receiving
18
F-PARPi with and without 127I-PARPi
before injection. C. Ex vivo biodistribution of
18
F-PARPi 1 h after injection in selected
tissue. ****P < 0.0001. Error bars represent
SD.

Figure 8 – Biodistribution of Intratumoral Injection of 131I-PARPi. A. Percent injected dose per
gram of tissue over four days. B. Tabulated biodistribution data.
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Figure 9 – Biodistribution of Intratumoral Injection of 131I-PARPi with
Blocking. A. Percent injected dose per gram of tissue over four days.
B. Tabulated biodistribution
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Bioluminescence and p53 Response
We designed and transduced a reporter cell line responding to p53 activation, a marker of
cell death and radiation damage. The cells coexpress p53/luciferase, together with constitutively
expressing SFGTurquoise/rsRluc. These bioluminescent reporters allow p53 expression to be
imaged after injection of luciferase, and cell density to be imaged after injection of coelenterazine.
Using this setup, we used bioluminescence imaging to determine p53 expression in relation to cell
density (Doubrovin et al. 2001). To
use this experimental setup for testing
whether

131

I-PARPi

retention

is

sufficient for inducing cell death,
mice

bearing

subcutaneous

transfected U87-p53 xenografts were
injected with 16.3 ± 1.5 MBq of 131IPARPi or vehicle (Figure 14). Dual
reporter

bioluminescence

was

measured 1 d before, on the day of,
and 24 and 48 h after

131

I-PARPi

injection. For the control groups, no

Figure 10 – 131I-PARPi Binding Specificity. A.
Autoradiography and H&E of subcutaneous U87-p53
xenografts 6 hours after injection with 131IPARPi with
or without a mass excess blocking dose of Olaparib. B.
Mean intensity of autoradiographic images. Nonparametric student’s t-test was used to calculate the
statistics. ** P < 0.005. Error bars represent the standard
deviation (SD).

statistical differences were observed for any time points, suggesting that vehicle alone did not
induce cell death (Figure 14). For mice injected with

131

I-PARPi, however, a statistically

significant increase in p53 signal was observed 24 h after administration of

131

I-PARPi, which

persisted at 48 h after injection (P < 0.005 after 24 h and P < 0.05 after 48 h when compared with
day 0).
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Therapeutic Efficacy of 131I-PARPi in Mouse Model of Glioblastoma
We next sought to determine the therapeutic efficacy of

131

I-PARPi in a subcutaneous

xenograft model of transduced U87-p53. For this purpose, tumor-bearing mice were randomly
assigned to 3 different cohorts (n = 9–10 per cohort): vehicle (30% PEG-300/PBS), nonradioactive
127

I-PARPi (5.9 µg, 9.9 nmol), or fractionated doses of 131I-PARPi (3 × 14.8 MBq, 3 × 9.9 nmol).
For the fractionated-dose cohort,
vehicle

and

intratumoral

127

I-PARPi

injections

were

cold

performed on days 0, 3, and 6.
Body weights and tumor volumes
Figure 11 – In Vivo Binding, Biodistribution, and
Pharmacokinetics. A. SPECT/CT images of subcutaneously
U87-p53–xenografted mice intratumorally injected with
(11.1 MBq) 131I-PARPi at time of injection and 6 h after
injection. B. Blocked mice received a systemic blocking
dose of Olaparib 1 h before 131I-PARPi. 131I-PARPi (14.8
MBq) biodistribution in key organs after intratumoral
injection at 1, 6, and 24 h (n = 4 per time point). C. 131IPARPi biodistribution in key organs at 1, 6, and 24 h
postintratumoral injection after systemic blocking via
intravenous injection of mass excess olaparib (n = 4 per time
point).

were recorded 3 times per week for
the length of the study (Figure
15B); neither cohort experienced
statistically significant weight loss,
confirming that the administered
activity did not lead to systemic
toxicity

(Figure

15B).

We

performed 2-sample t tests to compare tumor growth curves under dependent right censoring to
account for sacrifices due to ethical guidelines and applied a correction for the multiple pairwise
group comparisons (Figure 15D) (Vardi et al. 2001). No statistical difference of tumor volume was
observed between the vehicle cohort and the 127I-PARPi cohort. The fractionated-dose treatment
led to a statistically significant reduction in tumor volume compared with the vehicle group (P <
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0.005). This is also reflected in the
tumor growth rates, which were not
different at the beginning of the study
(week 0) but showed reduced growth
rates in the 2 radiotherapy groups at
week 2 compared with the control
group (Figure 16A). When comparing
survival of mice, statistical significance

Figure 12 – 131I-PARPi In Vivo Binding,
Biodistribution
and
Pharmacokinetics.
131
Biodistribution of I-PARPi in key organs over 96
hours (n=4/time point). B. Activity per gram of select
organs over 96 hours. C. Dosimetry of select organs 9
hours after 131I-PARPi injection.

was found for the treatment group versus the vehicle (P < 0.005). No statistical difference was
found between the vehicle group and cold 127I-PARPi. Mice receiving fractionated doses had the
longest median survival (29 d). Median survival for the PBS group and cold 127I-PARPi group was
22 and 20 d, respectively (Figure 16B).

Orthotopic Model
Simulating a potential clinical treatment scenario, we tested the delivery of 131I-PARPi in
an orthotopic U87-p53 mouse model of glioblastoma paired with an implantable osmotic pump
and cannula (Figure 17A). The osmotic pump mimicked slow, CED-type delivery of our
radiotherapeutic, and we compared the retention of

131

I-PARPi in tumor-bearing versus healthy

mice (Figure 18). On the basis of calculations of the administered dose from SPECT-derived pump
activity concentrations versus time, it was shown that administration of 30.7 MBq (49.2 MBq
initially implanted) resulted in the highest doses in the brain/tumor itself (30.1622 ± 0.1946
cGy/MBq ID), induced overwhelmingly by tumor-bound

131

I-PARPi (27.4405 ± 0.03784

cGy/MBq ID) versus photon dose from the pump contents (2.077 ± 0.100 cGy/MBq ID; Figure
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Figure 13 – Dosimetry of 131I-PARPi in Subcutaneous Model. A. Injected dose per gram of tissue
over 4 days after intratumoral injection. Organs of 32 mice were excised, weighed and counted
in a well scintillation counter. Average absorbed doses to the tumor and normal organs per MBq
injected activity is given in column 2 and per μCi in column 3. The ratio of the tumor to organ
dose is given in column 4. B. Tabulated dosimetry of key organs alongside ratio of tumor to
organ.
10). Other organs, affected primarily by g-radiation from the pump contents, received
comparatively small doses (Figure 17B). Only the left lung, which was in direct proximity to the
osmotic pump activity reservoir, received a somewhat elevated dose (11.08 cGy/MBq injected
dose). Experimental findings corroborated these models, as strong, durable retention of 131I-PARPi
was observed in tumor-bearing mice, whereas healthy brain tissue retained the radiotherapeutic to
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a much lower degree (Figure 17C);
after 6 d, 9.1 Gy were delivered to
the brains of tumor-bearing mice,
whereas healthy mice retained less
than 1 Gy.

Discussion
There is a critical need for
more and better therapeutic options
for patients with glioblastoma. The
past few decades have seen only
modest improvements in treatment
outcomes (Bianco et al. 2017). Both
PARP

inhibition

therapy

and

targeted radionuclide therapy are 2
new treatment approaches that have
independently gained widespread
attention; both types of therapy
have led to clinical trials, which are
currently ongoing (Begg et al.

Figure 14 – Bioluminescence Imaging of P53 Activation
in U87-P53 Cells. A. Average radiance (p/s/cm2/sr) of
subcutaneous U87-p53 tumors after intraperitoneal
injection of luciferin to image p53 expression. Images were
taken before and 48 hours after local injection of 131IPARPi radiotherapeutic (n=4). B. Average radiance
(p/s/cm2/sr) of subcutaneous U87-p53 tumors after
retroorbital injection of coelenterazine. Images were taken
before and 48 hours after local injection of 131I-PARPi
radiotherapeutic (n=4). C. Average radiance ratio of
luciferin and coelenterazine signals in mice that did
receive vehicle (20 μL 30% PEG300 in PBS). D. Average
radiance ratio of luciferin and coelenterazine signals in
mice that received 14.8 MBq dose of 131I-PARPi. * P <
0.05; ** P < 0.01.

2011). Here, we fuse these 2 approaches and use PARP as a target for a newly developed targeted
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radiotherapeutic. In this study, we sought to demonstrate a CED approach to delivering the
radiotherapeutic molecule 131I-PARPi in orthotopic glioblastoma models.

Figure 15 – Therapeutic Effect in a Subcutaneous Mouse Model. A. Treatment schedule of
fractionated doses. B. Body weights of mice throughout the study (n = 29). C. Individual
tumor volumes throughout study (n=29) D. Moving average of tumor volumes. (n = 9-10/cohort).
E. Difference of tumor growth percentage between cohorts at week 1 and week 3.
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In vitro and in vivo studies have shown that

131

I-PARPi is a potent PARP inhibitor, and

that introduction of radioiodine did not perturb binding specificity. This was also confirmed in a
12-member cross-family binding assay showing that 131I-PARPi possesses a binding profile akin
to olaparib and other olaparib-based imaging agents (Figure 4). PET imaging with
demonstrated that intratumoral administration of the cold iodinated analog

127

18

F-PARPi

I-PARPi perfused

efficiently throughout the tumor (Figure 5), confirming that the tissue permeability of the small
molecule is high, similar to what we found for PARPi-FL (Thurber et al. 2013). We also measured
the pharmacokinetics of the compound when administered intratumorally and observed strong
retention of activity in the tumor if PARP is available, but only very little when PARP binding
sites have been saturated with olaparib. Intuitively, the deposited dose is a function of the small
molecule’s tissue half-life, and the difference between the 2 is a function of target selectivity

Figure 16 – In Vivo Therapeutic Effect of 131I-Parpi Therapy in Subcutaneous Mouse Model A.
Difference of tumor growth percentage at beginning of study and at 2 wk. B. Kaplan–Meier plot
and table of treatment groups with median survival. Nonparametric Student t test was used to
calculate statistics for A. *P < 0.05. Error bars represent SD. P values were calculated by MantelCox test for B, P = 0.0001.
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(Figure 11). These data were used in dosimetric analysis, which showed that the tumor received
134.1 cGy/MBq while the major clearance organs, the thyroid and liver, received doses of 68.4
and 6.2 cGy/MBq, respectively. Using a fluorescently transfected cell line capable of reporting
p53 activation, we saw a statistically significant increase in p53 activation in subcutaneous mouse
models treated with 131I-PARPi (Figure 13). This activation serves as a marker of radiation damage
to cells, further verifying the therapeutic potential of 131I-PARPi. We then conducted a survival
study with the subcutaneous mouse model that showed a significant reduction in tumor growth

Figure 17 – In Vivo CED In Orthotopic Glioblastoma Mouse Model. A. Three-dimensional model
of orthotopic glioblastoma mouse model with CED-mimicking osmotic pump. B. SPECT/CT of
orthotopic U87-p53 tumors during osmotic pump treatment of 131I-PARPi at 72 h. C. Calculated
absorbed dose to brain* during treatment. *Brain and tumor have been considered together as a
single organ in organ-level dose calculation.
and improvement in median survival when 131I-PARPi was administered intratumorally as either
a single dose of 14.8 MBq or as a fractionated dose of 3 × 14.8 MBq (Figure 16). Low toxicity,
as a function of the mouse’s body weight, was observed throughout this study.
131

I-PARPi represents a theranostic pair in itself, insofar as it might be used for SPECT

imaging when delivered systemically in addition to its therapeutic function when delivered
intratumorally. However, in addition to SPECT, the 18F-labeled analog 18F-PARPi (Carney et al.
2016) can be used for PET imaging, which may be more suitable for patient stratification and
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treatment monitoring. Additionally, the fluorescently labeled analog PARPi-FL (Irwin et al. 2014)
might be used for fluorescence-guided resections.
A likely clinical scenario of

131

I-PARPi treatment involves the radiotherapeutics’

administration as a CED agent, similar to what has been shown previously for antibodies (Luther
et al. 2014).
instead

of

131

I-PARPi has structural similarity to olaparib, which features a cyclopropamide

the

131

I-labeled

meta-iodobenzamide.

Olaparib

is

a

substrate

of

phosphatidylglycerolphosphate synthase 1, a multidrug efflux transporter (Schinkel 1999;
Vaidyanathan et al. 2016). PGP might therefore be important in mediating 131I-PARPi uptake in
contrast-enhancing and non–contrast-enhancing regions of the brain, affecting both uptake and
clearance of drug, but potentially also improving selective uptake. To mimic a potential clinical
CED scenario, mice bearing orthotopic glioblastoma xenografts were treated with 131I-PARPi via
implanted osmotic pumps (Figure 17). Uptake and retention of 131I-PARPi in these mice were high,
as determined via periodic SPECT/CT measurement for up to 6 d after implantation. Healthy mice
showed no such retention. Dosimetry was calculated on the basis of the SPECT/CT data, indicating
that 9.1 Gy were delivered to the whole brain of a tumorbearing animal, whereas less than 1 Gy
was delivered to a healthy animal. This shows that CED delivers its radiotherapeutic dose in such
a way that PARP-overexpressing cells will retain the activity while the drug is cleared quickly
from healthy brain cells (Luther et al. 2014).

Conclusion
We have identified PARP1 as a potential anchor for radiotherapeutic PARP inhibitors in
glioblastoma. We explored and validated the pharmacokinetics and pharmacodynamics of

131

I-

PARPi and showed that animals treated with the radiotherapeutic have a survival benefit, and
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healthy brain cells do not retain
the radiotherapeutic.

Future

studies will need to show
131

whether

I-PARPi

demonstrates an improvement
in therapeutic efficacy over the
existing standard of care.

Materials and Methods
General
Unless

specified

otherwise, all reagents were
purchased

from

Sigma-

Aldrich and used as received.
131

I-Na in 0.1N NaOH with a

specific activity more than
4,600 TBq/g was purchased
Figure 18 – SPECT-CT Images of Orthotopic GBM Model with
Intracranial Osmotic Pump. A. Sagittal and transverse SPECT- from Nordion. 4-(4-fluoro-3CT image cross-sections of healthy mice treated with 131I-PARPi.
B. Cross-sections of mice with lesions and 131I-PARPi intracranial
(4-(3therapy. C. Sagittal MIPS of healthy mice during treatment. D.
Sagittal MIPS of diseased mice. E. Measured activity in pump.
iodobenzoyl)piperazine-1F. Activity administered to tumor.
carbonyl)benzyl)phthalazin1(2H)-one was synthesized as described previously (Salinas et al. 2015). Olaparib (AZD-2281)
was purchased from LC Laboratories. PARPi-FL was synthesized as previously described
(Irwin et al. 2014; Reiner et al. 2012). Water (>18.2 MWcm-1 at 25°C) was obtained from an
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Alpha-Q Ultrapure water system (Millipore) and acetonitrile (AcN) as well as ethanol (EtOH)
were of high-performance liquid chromatography (HPLC) grade purity. Sterile 0.9% saline
solution (Hospira) was used for all in vivo injections. HPLC purification and analysis were
performed on a Shimadzu UFLC HPLC system equipped with a DGU-20A degasser, a SPDM20A UV detector, a LC-20AB pump system, and a CBM-20A Communication BUS
module. A LabLogic Scan-RAM radio–thin-layer chromatography/HPLC detector was used
to detect activity. HPLC solvents (buffer A: water, buffer B: AcN) were filtered before use.
HPLC analysis and purification were performed on a reversed-phase C18 Waters Atlantis T3
column (C18-RP, 5 µm, 6 mm, 250 mm). Purification of the iodinated benzoic acid was
performed with method 1 (flow rate: 1 mL/min; gradient: 20 min 5%-95% B; 25 min 100%
B; 26 min 100%-5% B); quality control analysis was performed with method 1. Purification
of the final product was performed on a C6 Waters Spherisorb column (C6, 5 µm, 4.6 mm ×
250 mm) with method 2 (flow rate: 1.5 mL/min; isocratic: 0–30 min 35% B). SPECT imaging
was performed on a NanoSPECT/CT from Mediso Medical Imaging Systems. PET imaging
experiments were conducted on a Focus 120 MicroPET (Concorde Microsystems). Digital
phosphor autoradiography was obtained using a Typhoon FLA 7000 laser scanner from GE
Healthcare. g-counting and biodistributions were performed using a WIZARD2 automatic gcounter (PerkinElmer).

Synthesis of 127I-PARPi
4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one

(20

mg,

54.5

µmol) was dissolved in 1 mL of AcN and added to 10 mg (41.3 µmol) of 3-iodobenzoic acid,
followed by 25 mg (66 µmol) of N,N,N’,N’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium
hexafluorophosphate (HBTU) and 20 µL (145.5 µmol) of Et3N. The reaction mixture was
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stirred for 30 min and purified by HPLC (method 2) to yield the title compound (13.4 mg,
22.3 µmol, 67%). 1H-NMR (CDCl3) d = 10.48 (s, 1H), 8.40–8.39 (m, 1H), 7.74–7.66 (m, 5H),
7.27–7.26 (d, 2H), 7.09–7.07 (d, 2H), 4.22 (s, 2H), 3.73–3.14 (m, 8H). LC-ESI-MS (+) m/z
= 597.1 [M+H+] +. HRMS-ESI [M-H+]- m/z calculated for [C27H22FIN4O3]- 595.0642, found
595.0640.

Synthesis of 18F-PARPi
18

F-PARPi was synthesized as described by Carney et al. ((Carney et al. 2016)). Briefly,

a QMA cartridge containing cyclotron-produced
solution

containing

9

mg

of

Kryptofix

18

F-fluoride (n.c.a.) was eluted with a

[2.2.2]

(4,7,13,16,21,24-hexaoxa-1,10-

diazabicyclo[8.8.8]hexacosane), 0.08 mL of 0.15 M K2CO3, and 1.92 mL of AcN into a 5-mL
reaction vial. Then, ethyl 4-nitrobenzoate (500 µg in 100 µL of dimethyl sulfoxide [DMSO])
was added to the azeotropically dried

18 -

F and heated to 150°C (15 min). After this time, 50

µL of 1M NaOH were added followed by HCl (1M, 50 µL) 1 min later. Then, 2 mg of 4-(4fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one (in 100 µL of DMSO) were
added followed by 10 mg of HBTU in 100 µL of DMSO. Finally, 20 µL of Et3N were added
and the reaction mixture was further diluted with 400 µL of AcN and 1 mL of H2O. The crude
mixture was purified by HPLC. The decay-corrected radiochemical yield for the final step
was 38.4 ± 2.5% with a molar activity (MA) of 35.9 ± 15.2 GB/µmol. The purified final
compound was formulated with 10% EtOH/0.9% NaCl 0.9%.

Synthesis of 131I-PARPi
131

I-PARPi was obtained in a manner similar to synthetic procedures reported before

((Salinas et al. 2015)). First,

131

I-NHS-benzoate was obtained by adding N-succinimidyl-3-
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(tributylstannyl) benzoate (30 µg, 5.9 µmol) in 30 µL of AcN to a solution containing
methanol (40 µL), chloramine T (6 µg, 30 nmol), acetic acid (2 µL), and 131I-NaI in NaOH
0.1 M (185–370 MBq [5–10 mCi]). After the reaction solution was driven for 15 min at room
temperature, the reaction was purified by HPLC (method 1), and 131I-NHS-benzoate collected
at 15.1 min. The collected purified fraction was concentrated to dryness in vacuum,
reconstituted in a solution of 80 µL of AcN, and added to a solution of 4-(4-fluoro-3(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one (0.3 mg, 0.9 µmol) in 20 µL of DMSO
and HBTU (0.3 mg, 0.8 µmol) in 20 µL of DMSO; 10 µL of 2,6-lutidine were further added
and the reaction mixture stirred in an Eppendorf ThermoMixer overnight at 65°C (500 rpm).
The following day, the reaction mixture was injected and purified by HPLC (method 2) and
the final 131I-PARPi was collected at room temperature for 13.1 min (radiochemical yield >
70%; radiochemical purity > 99%) and concentrated to dryness under vacuum.

131

I-PARPi

was formulated with 30% PEG300/70% saline (0.9% NaCl) for both in vitro and in vivo
assays (MA = 1.5 ± 0.3 GBq/µmol). Coelution with nonradioactive

127

I-PARPi reference

compound confirmed the identity of the radiotherapeutic.

PARP Inhibitor Binding Assays
Assay was performed by BPS Bioscience. DMSO solutions (100 µM) of each inhibitor
were provided at a 100 nM, 50 nM, or 10 nM concentration. Measurements for each enzyme
combined with each inhibitor were performed in triplicate in accordance with the BPS assay
kit protocol (Brown and Marala 2002). Luminescence was measured using a BioTek Synergy
2 microplate reader. Data were reported by BPS as percentage enzyme activity. Triplicates
were combined to get a mean ± SD, which was then grouped and plotted onto a heat map
using GraphPad Prism 7 (GraphPad Software).
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Cell Culture
The human glioblastoma cell line U251 MG was kindly provided by the Laboratory of
Dr. Ronald Blasberg (Memorial Sloan Kettering Cancer Center [MSKCC]). Cell lines were
grown in Eagle’s minimal essential medium (MEM), 10% (vol/vol) heat-inactivated fetal
bovine serum, penicillin 100 IU2, and streptomycin (100 µg/mL), purchased from the culture
medium preparation facility at MSKCC.

Transduction Procedure of U87 Cell Line
U87 human glioblastoma cells were grown in MEM with 10% fetal calf serum. The
retroviral transient producer cell line H29 was maintained in Dulbecco MEM supplemented
with 10% fetal calf serum, puromycin (2 µg/mL), and tetracycline (1 µg/mL), transfected with
Cis-p53/tdTomato-CBRluc-Neo and incubated for 48 h. The U87 cells were transduced with
the Cis-p53/tdTomato-CBRluc-Neo later using H29-produced virus by incubating 30%
confluent tumor cell culture with retroviral vector-containing medium for 48 h. Transduced
U87-p53/tdTomato-CBRluc-Neo cells (short: U87-p53) were selected by culturing in MEM,
supplemented with 10% fetal calf serum and G418 sulfate (0.5 mg/mL) (Corning, catalog no.
30-234-CR). Several fluorescence-activated cell sorting (FACS) sorting procedures were
performed to enrich cells with a low background of p53 activity. Selected cells were
additionally transduced with a second constitutively expressed SFG-Turquoise/rsRluc virus
as described above.
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Cell-Internalization, Targeting Specificity, and Binding Properties
U251 MG cells were adhered overnight in 6-well plates (1 million cells/well) and
washed twice with phosphate-buffered saline (PBS) prior to addition of

131

I-PARPi (222

kBq/well, 0.15 nmol) at 37°C for 0, 15, 30, 45, 60, 120, and 240 min in MEM to allow for
binding. Binding specificity was challenged with a 50-fold excess of olaparib (3.26 µg, 7.5
nmol). Next, at each time point, cells were first washed twice with PBS 1× and then lysed by
incubation with 1 M NaOH (10 min at 37°C). Finally, the resulting lysate in each well was
collected and the radioactivity measured in an automated g-counter. Targeting specificity was
assessed by a competitive binding assay between 127I-PARPi and PARPi-FL. U251 MG cells
(50,000 cells/well) were plated 48 h before the experiment. On the day of the experiment,
binding affinity was determined by coincubating the plated cells (37°C, 40 min) with serial
dilutions of

127

I-PARPi, ranging from 0 to 10 µM and 0.5 µM PARPi-FL. After this time,

cells were washed twice with PBS 1×, fixed, and counterstained with Hoechst DNA stain.
PARPi-FL uptake and blocking effects were observed and measured by confocal microscopy.

Mice
Female athymic nude CrTac:NCr-Fo mice were purchased from Taconic Laboratories
at age 6–8 wk. Xenograft-bearing mice were used to determine all pharmacokinetics, the
binding/imaging properties, and the treatment efficacy of the radiotherapeutic (ntotal = 98).
During subcutaneous injections, mice were anesthetized using 2% isoflurane gas in 2 L/min
medical air. During orthotopic injections, mice were anesthetized using a 150 mg/kg ketamine
and 15 mg/kg xylazine cocktail (10 µL/g of body weight). For intravenous injections, the
lateral tail vein was used. Mice were warmed with a heat lamp and placed in a restrainer, and
the tail was sterilized with alcohol pads before injection. U251-MG or U87-p53 cells were
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implanted subcutaneously (5 × 106 cells in 150 µL of 1:1 PBS/Matrigel [BD Biosciences])
into the right shoulder and allowed to grow for approximately 2 wk until the tumors reached
about 8 mm in diameter (100 ± 8 mm). For orthotopic injections, U251 MG or U87-p53 cells
(5 × 105 cells in 2 µL of PBS) were injected 2 mm lateral and 1 mm anterior to the bregma
using a Stoelting Digital New Standard Stereotaxic Device and a 5-mL Hamilton syringe and
allowed to grow for approximately 3 wk. All mouse experiments were performed in
accordance with protocols approved by the Institutional Animal Care and Use Committee of
MSKCC and followed National Institutes of Health guidelines for animal welfare.

SPECT/CT
SPECT/CT scans were obtained using a small-animal NanoSPECT/ CT from Mediso
Medical Imaging Systems. For subcutaneous U251 MG xenografts,

131

I-PARPi (11.1 MBq,

1.5 GBq/µmol in 20 µL of 30% PEG300 in 0.9% sterile saline) was administered
intratumorally (n = 3). At 0 and 6 h after injection, the mice were anesthetized with 1.5%–
2.0% isoflurane (Baxter Healthcare) at 2 mL/min in oxygen, and SPECT/CT data were
acquired for 20 min. For orthotopic U251-MG tumor–bearing mice,

131

I-PARPi (1.9 MBq,

1.5 GBq/µmol in 5 µL of 30% PEG300 in 0.9% sterile saline) was injected intracranially
using the same coordinates as for tumor cell injection (2 mm lateral and 1 mm anterior to the
bregma using a Stoelting Digital New Standard Stereotaxic Device and a 5-µL Hamilton
syringe). At 24 h after injection, the mice were anesthetized with 1.5%–2.0% isoflurane
(Baxter Healthcare) at 2 mL/min in oxygen, and SPECT/CT data were collected for 20 min
in the head region.
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Autoradiography and Hematoxylin and Eosin Staining
Twenty-four hours after intratumoral injection of

131

I-PARPi or olaparib/131I-PARPi

in U251 MG subcutaneous xenograft–bearing mice, mice were sacrificed, and tumors were
harvested. The collected organs were embedded in Tissue-Tek O.C.T. compound (Sakura
Finetek), flash-frozen in liquid nitrogen, and cut into 20-µm sections using a Vibratome
UltraPro 5000 Cryostat (Vibratome). A storage phosphor autoradiography plate (BASMS2325; Fiji Photo Film) was exposed to the tissue slices overnight at -20°C and read the
following day. Relative count intensity of the sections in each image was quantified using
ImageJ 1.47u processing software (NIH). Tumor-to-muscle and brain-to-muscle ratios were
calculated using Prism 6.0c (GraphPad Software). Sections were subsequently subjected to
hematoxylin and eosin staining for morphologic evaluation of tissue pathology.

PET/CT Imaging
Small-animal PET imaging data were recorded on a Focus 120 MicroPET (Concorde
Microsystems) and reconstructed using AsiPro VM MicroPET Analysis software (Siemens
Medical Solutions). 18F-PARPi (5.55 MBq, 35.89 ± 15.17 GBq/µmol in 300 mL, 10% EtOH
in 0.9% sterile saline) alone or following an intratumoral injection of 127I-PARPi (10 µg, 16.5
µmol, 20 µL, 30% PEG300/70% NaCl 0.9% 6 h before

18

F-PARPi injection) was injected

into U251 MG tumor–bearing mice (n = 3) via the tail vein. At 2 h after injection, the mice
were anesthetized with 1.5%–2.0% isoflurane (Baxter Healthcare) at 2 mL/min in oxygen,
and PET/CT imaging was performed over 15 min. Images were analyzed using AsiPro VM
software (Concorde Microsystems). Then, mice were sacrificed, and key organs harvested for
quantification and autoradiography/hematoxylin and eosin staining.
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Ex Vivo Biodistribution and Dosimetry (Subcutaneous Model)
Biodistribution studies were performed in subcutaneous U251 MG xenograft–bearing
athymic nude mice (n = 44, 11 randomized cohorts, 4 mice per cohort). Mice were divided
into 2 groups (blocked and unblocked), and 131I-PARPi (0.56 MBq, 1.5 GBq/µmol in 20 µL,
30% PEG300 in 0.9% sterile saline) was administered intratumorally. The blocked group was
preinjected 30 min before

131

I-PARPi with olaparib (8.15 µg, 18 nmol in 100 µL, 30%

PEG300/70% NaCl 0.9%). Mice were sacrificed by CO2 asphyxiation at 1, 3, 6, 12, 24, 48,
72, and 96 h after injection (for 131I-PARPi–only groups) and at 1, 6, and 24 h after injections
(for blocking experiments groups), and major organs were collected, weighed, and counted in
a WIZARD2 automatic g-counter (PerkinElmer). The 131I-PARPi uptake was expressed as a
percentage of injected dose per gram (%ID/g) using the following formula: [(activity in the
target organ/g of tissue)/injected dose] × 100% (Supplemental Figs. 5 and 6). The average of
the 4 organ specimens from each time point was fitted to a biexponential function. The best
fit for most organs comprised a 2-phase exponential clearance model. For 2 organs (the
thyroid and large intestine), there was measured uptake over the first 12 h, and therefore these
organs were fitted to an uptake and clearance exponential model. Cumulative uptake was
calculated from the areas under the tumor uptake curves. Absorbed doses to tumor and all
normal organs were estimated assuming absorbed fractions of 1 for the 𝛽-emissions of

131

I

and 0 for the penetrating photon emissions and using an equilibrium dose constant of 0.111 g
Gy/MBq h (0.405 g cGy/µCi h). The ratio of tumor to normal organ dose exceeded 20 for all
organs except the thyroid (Figure 9). The high dose to the thyroid gland was a likely
consequence of the deiodination followed by uptake and then slow clearance (evidence of
trapping in the thyroid tissue) (Figure 13).
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Bioluminescence
Bioluminescence studies were performed in subcutaneous U87-p53 xenograft–bearing
mice (n = 8, 4 mice per cohort). Mice were divided into 2 groups (treated and untreated). For
treatment, mice were administered

131

I-PARPi (14.8 MBq, 1.5 ± 0.3 GBq/µmol in 20 µL,

30% PEG300 in 0.9% sterile saline) intratumorally. The untreated group received an
intratumoral injection of a 30% PEG300 solution in 0.9% sterile saline (20 µL). Imaging was
performed on an IVIS Spectrum preclinical in vivo imaging system from PerkinElmer the day
before treatment (baseline) and on day 0, 1, and 2 after treatment. For detection of the
constitutively expressed SFG-Turquoise/rsRluc reporter, mice were given a retroorbital
injection of 10 µg of coelenterazine h ((2-(4-dehydroxy)coelenterazine from Biotium) dissolved
in 5% ethanol in 0.9% sterile saline solution and imaged within 22 s of injections. For detection
of p53 activation (Cis-p53/tdTomato-CBRluc-Neo), mice were imaged 20 min after an
intraperitoneal injection of 2 mg of luciferin/100 µL of sterile 0.9% NaCl solution.

Therapeutic Efficacy
Therapeutic efficacy studies were performed in subcutaneous U87-p53 xenograft–
bearing mice (n = 29, 3 randomized groups, 9–10 mice per cohort). Mice were divided into 3
cohorts (vehicle, nonradioactive/cold 127I-PARPi, and 3 × 14.8 MBq of 131I-PARPi). The cold
group received mass equivalent doses (6 µg) of
131

127

I-PARPi. Vehicle,

127

I-PARPi, and 3 ×

I-PARPi were administered on day 0, 3, and 6 via intratumoral injections. Body weights

were recorded every Monday, Wednesday, and Friday until tumor burden exceeded the
endpoint of 800 mm. Additional supporting tables and figures can be found in the
supplemental materials. All animal experiments were performed in accordance with protocols
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approved by the Institutional Animal Care and Use Committee and followed the National
Institutes of Health guidelines for animal welfare.

Orthotopic CED Model
Mice received intracranial injections of U87-p53 cells (5 × 104 cells in 1.5 µL of PBS).
After 3 wk, bioluminescence imaging was used to determine presence of tumor. Then, we
surgically implanted an ALZET Osmotic Pump into the mice, which slowly delivered an
infusion into the brain using the same coordinates as for the tumor cell injection. Both healthy
and diseased mice received an ALZET Osmotic Pump (Model 1003D) with Brain Infusion
Kit 3 containing 131I-PARPi (40.7 ± 11.1 MBq in 101 × 8 µL 30% PEG300/70% NaCl 0.9%).
Pumps were weighed before and after filling to calculate added volume, as per the
manufacturer’s instruction. After filling pumps and assembling catheter and cannula, infusion
kits were incubated in 0.9 % saline at 37°C overnight to ensure flow was initiated (1.0 µL/h
[±0.15 mL/h]) and air bubbles were removed. Immediately before implantation, pumps were
measured in dose calibrators to measure activity in pumps at time of surgery. SPECT/CT
images were acquired 1 h after surgery and again at 12 h. Mice were imaged every 24 h for 6
days. After the fifth day, the pumps were surgically removed, and the remaining dose was
measured in dose calibrators to ensure payload had been delivered. The image volumes were
segmented using a com- bination of manual and semiautomatic segmentation techniques in
3D Slicer, version 4.6 (www.slicer.org) for quantification of absolute activity in different
organs at each time point. The presence of activity levels above background in the SPECT
images was not observed except in the brain/tumor and the osmotic pump.
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Dosimetry (CED)
Source/Target Definition. The popular Digimouse atlas (Dogdas et al. 2007) was used as a
digital phantom for dosimetry calculations. The atlas was adapted in the open-source 3dimensional modeling software Blender to incorporate models of the osmotic pump, tumor,
and thyroid tissues. The adapted model was tetrahedralized via the Delaunay method in the
mesh generation software Tetgen to construct a 3-dimensional finite element mesh suitable
for implementation in the Particle and Heavy Ion Transport Simulation (PHITS) Monte Carlo
code (Sato et al. 2013). Material attributes for each region were assigned as soft tissue, lung,
or bone using standard International Commission on Radiological Protection reference data
for atomic composition and density (www. physics.nist.gov).

Calculation of Injected Activity. The rate of injection of 131I activity into the tumor is:
-./
-0

=−

-.3
-0

− 𝜆𝐴6

Eqn. 1

where, Ai = injected activity (µCi), Ap = activity in pump (µCi), l = radioactive decay constant
(h-1), and t = time after implantation (h). Given Ap = A0 at t = 0, the cumulative injected activity
is obtained following solution of Equation 1 using an integrating factor or transform methods:
0

𝐴7 = 𝐴8 − ∫8 𝐴6 𝑑𝑡 − 𝐴6

Eqn. 2

where, A0 = initially implanted activity (µCi). A0 was determined by measuring the activity present
in the pump in a dose calibrator immediately prior to implantation. Ap at different time points was
determined from SPECT imaging volume-of-interest analysis. The resulting time–activity curve
was fit as a 1-phase exponential decay; the fitted curve was then implemented for calculation of
the injected activity via Equation 2 (Figure 18E).
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Theoretical Estimation of Injected Activity. For the theoretical case, wherein the pump contents
are introduced at a constant flow rate κ (cm3/h), and assuming the 131I-PARPi activity is
uniformly distributed in the pump contents the injection rate is:
𝜅𝜌 =
𝑑𝐴7=
=
>
𝑑𝑡

𝜅𝐴8
𝑉
G B CDE 𝑓𝑜𝑟 𝑡 ≤ 8=𝜅
𝑉8
,
𝑉
0, 𝑓𝑜𝑟 𝑡 > 8=𝜅

Eqn. 3

where,
V
𝜅 = 𝑣𝑜𝑙𝑢𝑚𝑒𝑡𝑟𝑖𝑐 𝑓𝑙𝑜𝑤 𝑟𝑎𝑡𝑒 U𝑐𝑚 = X
ℎ

𝜌 = 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 U𝜇𝐶𝑖= V X
𝑐𝑚
𝑉8 = 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑝𝑢𝑚𝑝 𝑐𝑜𝑛𝑡𝑒𝑛𝑡𝑠 (𝑐𝑚V )
The theoretical injected dose follows after integration in time, from 0 to t:
𝜅𝐴8
𝑉
=𝜆𝑉 a1 − 𝑒 bc0 d, 𝑓𝑜𝑟 𝑡 ≤ 8=𝜅
8
𝐴7 = >
bcef=
𝜅𝐴8
g X , 𝑓𝑜𝑟 𝑡 > 𝑉8=
=𝜆𝑉 U1 − 𝑒
𝜅
8

Eqn. 4

The activity present in the osmotic pump may be expressed by substitution of Eqn. 3 into Eqn.
1 and rearranging, viz:
𝑑𝐴6
= + 𝜆𝐴6 = − 𝜅𝐴8G
𝑑𝑡
𝑉

8

Eqn. 5

B CDE

Given 𝐴6 = 𝐴8 when𝑡 = 0, this initial value problem may be solved using an integrating factor
or transform methods, yielding:
U𝐴8 =
𝐴6 = >

𝜅𝐴8 𝑡
𝑉
=𝑉 X 𝑒 bc0 , 𝑓𝑜𝑟 𝑡 ≤ 8=𝜅
8
𝑉
0, 𝑓𝑜𝑟 𝑡 > 8=𝜅
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Eqn. 6

Monte Carlo Simulation. PHITS was used to generate decay events in each source via rejection
sampling; betas and photons were simulated using a spectrum of beta energies obtained from the
RADAR database (www.doseinfo-radar.com) for

131

I, gamma and x-ray spectra were obtained

from the International Atomic Energy Agency Nuclear Data Center (www-nds.iaea.org), and a 3keV energy cutoff was used. The activity in each source tissue is assumed to be distributed
uniformly and is assigned a random initial direction vector. Total events (1–5 × 106) were
simulated, resulting in less than 10% relative error in energy deposit in relevant target tissues.
Absorbed doses were output either in units of Gy or normalized to the injected activity calculated
using Equation 2 (Gy/µCi). Three-dimensional dose maps were rendered in Paraview (Sandia
National Laboratory, Kitware Inc., Los Alamos National Laboratory).
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CHAPTER THREE - Targeted Brain Tumor Radiotherapy Using an Auger Emitter

The following chapter was reproduced from the submitted manuscript to Clinical Cancer
Research “Targeted brain tumor radiotherapy using an Auger emitter” Co-authored by Pirovano
& Jannetti et al. 2019 (Pirovano et al. 2019).

Introduction
Glioblastoma multiforme (GBM) is one of the deadliest forms of solid tumors, with a 5year survival rate as low as 5% (Alexander and Cloughesy 2017). Clinical intervention typically
consists of maximal safe surgical resection followed by adjuvant chemo-radiotherapy. This
therapeutic regimen, unfortunately, imparts only limited improvements to survival (Bi and
Beroukhim 2014). Additionally, the GBM molecular heterogeneity represents a robust challenge
in need of better imaging tools that would allow for the monitoring of therapy response and lead
to better and more personalized therapeutic plans. Furthermore, the presence of the blood-brain
barrier (BBB) biochemically limits the pharmacokinetics of many GBM drug candidates.
A novel approach for treating GBM is therefore urgently needed, one that would address both
pharmacodynamic as well as pharmacokinetic hurdles (Dong 2018; Parker et al. 2015). Promising
delivery strategies to overcome these obstacles in the clinics include aligning novel targeting
schemes with improved drug delivery approaches including convection enhanced delivery (CED)
(Anjum et al. 2017; Vogelbaum and Aghi 2015) and intrathecal injection (Kommidi et al. 2017;
Oberoi et al. 2015).
A known molecular biomarker for most tumors, including GBM, is poly(ADP-ribose)
Polymerase 1 (PARP1) (Bouchard et al. 2003; Carney et al. 2017; De Murcia et al. 1997; Galia et

52

al. 2012; Irwin et al. 2014; Ossovskaya et al. 2010; Tang et al. 2017). PARP1 is recruited to the
nucleus of cancer cells and binds DNA as a single-strand break (SSB) repair enzyme (Ko and Ren
2012). This central role has been successfully leveraged for the development of various PARP
inhibitors, both as a monotherapy and in combination with other therapeutics (Bryant et al. 2005;
Farmer et al. 2005). Modified PARP inhibitors have also been widely used for tumor detection and
imaging due to their cancer specificity and their high target-to-background contrast (Anderson et
al. 2016; Carney et al. 2017; Carney et al. 2018; Donabedian et al. 2018; Gonzales et al. 2018;
Irwin et al. 2014; Kossatz et al. 2017a; Kossatz et al. 2017b; Makvandi et al. 2016); more recently,
they have found theranostic applications (Jannetti et al. 2018).
Here, we focus on PARP1-based radiotherapy with a more sporadically utilized type of
radioactive emission: Auger radiation. Auger emitters are an extremely potent radioactive source
for targeted radiotherapy, characterized by their greater linear energy transfer, incredibly short
range, and ability to cause a complex, lethal DNA damage as compared to traditional X-rays or bparticles (Bavelaar et al. 2018; Buchegger et al. 2006; Daghighian et al. 1996; Kiess et al. 2015;
Welt et al. 1996). Previous attempts to use Auger emitters as cancer therapies have not been
successful, due to the limited range of the radiation emitted and the difficulty of reliably delivering
the lethal electrons close enough to the DNA target (< 100 Å) (Hofer and Hughes 1971; Bavelaar
et al. 2018; Kassis 2003).
In this study, we developed and characterized 123I-MAPi, the first Auger-based theranostic
PARP inhibitor able to directly deliver its lethal payload within a 50-angstrom distance of the
DNA of GBM cancer cells (Figure 19A). This distance is within the Auger radius of action,
resulting in an effective preclinical cancer treatment drug and leading to improved survival in a
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preclinical GBM model. We used the 159 keV gamma ray to image tumor progression using
SPECT imaging and calculate dosimetry and treatment efficacy using SPECT imaging.

Figure 19 – 123I-MAPi Synthesis, Binding, and Efficacy in Vitro. A. 123I-MAPi binding to
PARP1 can deliver lethal Auger radiation within ~100 Å, enough to affect DNA in cancer
cells when bound. B. RP-HPLC coelution of 123I-MAPi with nonradioactive I-127 analog.
C. Synthetic scheme of 123I-MAPi, (a) 0.1 M NaOH, Chloramine T, AcOH, MeOH 20 m,
RT; (b) 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one, HBTU,
DMAP, 2,6-Lutidine, DMSO, ACN, 2 h, 65 °C. D. Cellular uptake of 123I-MAPi in U251
GBM cell line. Blocking performed with 100-fold incubation of Olaparib prior to treatment.
Sodium Iodine-123 represented by red line. Michaelis-Menten curve fitting. E. Alamar
Blue assay comparing 123I-MAPi efficacy with Olaparib at equal molar concentrations. 123IMAPi EC50 = 69 nM. Nonlinear fit four parameters variable slope.
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Taken together, these results illustrate the tremendous potential of 123I-MAPi as an Augeremitting PARP inhibitor and a theranostic agent for GBM treatment.

Results
Synthesis of 123I-MAPi and in vitro Validation
We previously showed that it is possible to successfully conjugate a PARP inhibitor with
radioiodine without altering the high affinity to the target – maintaining an IC50 in the nanomolar
range (11 ± 3 nM) and a logPCHI of 2.3 (Salinas et al. 2015).

123

I-MAPi is a novel, previously

unreported isotopologue, and was synthesized with a final molar activity of 3.93 ± 0.10 GBq/μmol.
Radiochemical purity was 99.1 ± 0.9% for all prepared compounds (Figure 19B).
Pharmacological properties determined with

127

I-PARPi suggest that

123

I-MAPi (Figure

19C, 20A), retains the same properties as 131I-PARPi, which have been shown to be similar to the
FDA-approved PARP inhibitor Olaparib (Jannetti et al. 2018; Salinas et al. 2015).
In vitro internalization was tested on U251 cells expressing PARP1 (Figure 19D, 20B).
123

I-MAPi (37 kBq/well) was added to adherent cells in monolayer and uptake was calculated by

measuring gamma radiation in cell lysates at different time points. We confirmed rapid cellular
internalization, with 50% of the final total uptake being reached after 5 – 10 minutes postincubation and with an uptake plateau reached at 1 h post-treatment. The final total uptake was
~8% of added activity, Vmax = 8.2 ± 0.2 % compared to blocked uptake, Vmax = 3.8 ± 0.1 %
(Michaelis-Menten fit, R2 = 0.974 and R2 = 0.879, respectively). Uptake was blocked with a 100fold excess dose of Olaparib to show target specificity. Na-123I was used as a control and showed
significantly lower uptake, Vmax = 2.5 ± 0.1. The two dominant targets for 127I-PARPi, the stableisotope labelled form of the molecule, are PARP1 and PARP2 (Jannetti et al. 2018), similar to
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what has been previously reported for Olaparib and other modified PARP inhibitors (Carney et al.
2017).
We tested the cancer-specific efficacy of 123I-MAPi in vitro by treating U251 GBM cells
with

123

I-MAPi. Comparing

123

I-MAPi with the previously published beta-emitting

131

I-PARPi,

we observed a 16-fold increase in EC50 potency (EC50 of 131I-PARPi being 1148 ± 1 nM, Figure
20C).

123

I-MAPi treatment proved to reduce viability at safe concentrations of

123

I-NaI (Figure

20D, E). Critically, in the molar concentration range used in these studies, Olaparib showed
negligible effect in terms of cell viability, demonstrating that clonogenic inactivation arises
exclusively from I-123 radiotoxicity as opposed to PARP1 inhibition (Figure 19E).

123

I-MAPi

proved to be capable of killing cancer cells with a sub-micromolar EC50 (EC50 = 68.9 ± 1.1 nM,
R2 = 0.999). At the same concentrations, Olaparib did not show any effect in terms of cell viability,
suggesting that the observed effect is due to the PARP1 inhibitor-mediated close proximity to the
target DNA.

Figure 20 – Molecular Structures, Target Expression, and In Vitro Assays. A. Western Blot
of PARP1 in glioblastoma cell lines with 𝛽-actin control. B. Molecular structure of Olaparib,
123
I-MAPi, and 127I-PARPi, 123I-MAPi isotopologue. C. Alamar Blue assay comparing 123IMAPi and 131I-PARPi at equal molar concentrations. 123I-MAPi EC50 = 69 nM, 131I-PARPi
EC50 = 1148 nM. Nonlinear fit four parameters variable slope. D. Clonogenic assay and E.
Almar Blue viability assay of 123I-MAPi vs. sodium iodine-123 in U251 GBM cells.
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Figure 21 – Immunohistochemistry of 123I-MAPI DNA Damage in Vitro. A. Example of 123IMAPi treated cells. B. Example of 127I-PARPi treated cells. C. Example of cells treated with
vehicle control. Images showing immunofluorescence of γ-H2AX (red), DAPI nuclear
staining (blue), PARP1 expression (green), and merged images. D. Quantification of the
number of γ-H2AX foci within the nucleus of cells after treatment with 123I-MAPi (n = 85),
127
I-PARPi (n = 125), and vehicle control (n = 140). ***p-value < 0.001, Kruskal-Wallis test.
In order to characterize the induction of DNA damage in cancer cells after treatment with
123

I-MAPi, we performed immunofluorescence analysis of the levels of γ-H2AX foci, a known

marker for double-strand breaks (Rogakou et al. 1998). We treated U251 GBM cells with 740 kBq
123

I-MAPi in 20 μL of 30%PEG/PBS added to the media in each well (2 mL) and compared it to

the equivalent dose of non-radioactive 127I-PARPi and vehicle control (Figure 21A,B, and C). 123IMAPi treated cancer cells showed a significantly higher number of γ-H2AX foci in the cell nucleus
(***p-value < 0.001, Kruskal-Wallis test), Fig 21D.)
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Efficacy of 123I-MAPi in a colony formation assay.
We tested 123I-MAPi in comparison with externally applied photon radiation and assessing
clonogenic survival (Figure 22A). Colony formation assay (CFA) was performed in 6-well plates
to compare efficacy of

123

I-MAPi in cell killing when compared to standard external beam

irradiation (EBIR). U251 GBM cells were plated and treated with Cs-137 γ-rays (662 keV) or by
adding 123I-MAPi to the wells (Figure 22A).
As expected with high LET radiation treatment, cells treated with the Auger-emitting small
molecule showed a steep decline in survival, confirming the high efficacy in tumor cell killing

Figure 22 – Assessment of 123I-MAPi DNA Damage in Vitro. A. Survival of U251 cells
following in vitro 123I-MAPi labeling and incubation/colony formation, in comparison to
external irradiation. B. Tetrahedral mesh cell phantom utilized for Monte Carlo dose
calculation in PARaDIM software.
when compared to EBIR (Figure 22B). We derived first-order estimates of relative biological
effectiveness of on-target

123

I-MAPi through cell dosimetry calculations, which suggest a

remarkable increase in therapeutic potency when 123I-MAPi is bound to PARP1 (i.e. when DNA
is within reach of its Auger emissions). Radiobiological parameters were calculated after linearquadratic model fit of the data: 123I-MAPi α = 19.8 Gy-1, β = N/A. EBIR α = 0.269 Gy-1, β = 0.0588
Gy-1. 123I-MAPi D37 = 0.05 Gy, EBIR D37 = 2.41 Gy. Relative biological effectiveness (RBE) was
calculated for 123I-MAPi: RBE at D37 = 48.4, RBE (αI-123/ αEBIR) = 73.4 (Table 1).
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Biodistribution and toxicity of 123I-MAPi in vivo.
TS543 patient-derived glioblastoma stem cells were used to grow tumors in athymic nude
mice in order to investigate the biodistribution of 123I-MAPi. Tumors were grown subcutaneously
on the animals’ right shoulder. Mice were then randomized and divided into two cohorts (n =
3/group) one of which was used for blocking. Blocking was performed systemically with an
intravenous injection of Olaparib 1 h prior to

123

I-MAPi treatment.

intratumorally for this model. SPECT/CT images showed that

123

123

I-MAPi was injected

I-MAPi tumor uptake was

retained at 1 h, 6 h and 18 h post injection in non-blocked animals, but was strongly reduced at 6
h and 18 h in blocked animals (Figure 23A, 24A). Biodistribution at 18 h was also examined and
showed higher tumor uptake (33.4 ± 28.0 % ID/g) compared to the tumor of blocked animals (0.4
± 0.1 % ID/g) (Figure 23B). Tumor-to-muscle ratios in

123

I-MAPi treated mice versus blocked

mice were > 500 and 5, respectively, with less than 1% ID/g in all clearing organs.

Table 1 - Determination of Radiobiological Parameters for The L-Q Model and RBE.

123

I-MAPi
EBIR

123

I-MAPi
EBIR

123

Radiobiological parameters
α (Gy-1)
β (Gy-1)
19.8
-0.269
0.0588
D37 (Gy)
0.05
2.41
Relative biological effectiveness (RBE)
RBE at D37
RBE (αI-123/
αEBIR)

I-MAPi

48.4
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73.4

Auger particles are highly cytotoxic when they can directly interact with the DNA and
cause complex damage. However, they are significantly less so in the cellular cytosol, where they
are beyond the reach of their DNA target (Buchegger et al. 2006). As liver clearance is the main
route of excretion of

123

I-MAPi that could cause dose-limiting problems in the clinic, we

investigated potential clinical liver failure by observing specific liver toxicity in our preclinical
study. We compared tumor and liver accumulation of PARPi-FL, a thoroughly characterized

Figure 23 – Imaging and Biodistribution of 123I-MAPi in Subcutaneous TS543 Mouse
Model. A. Specific tumor uptake of 123I-MAPi at 18 h after local injection. Blocking was
performed intravenously 1 h before injection. T = tumor, Th = thyroid. B. Ex vivo
biodistribution of 123I-MAPi at 18 h after local injection. C. Uptake of PARPi-FL in tumor
and liver of TS543 tumor-bearing mice show nuclear uptake for tumor and cytoplasmic
uptake for liver tissue. D. Quantification of PARPi-FL uptake in the nucleus and cytoplasm
of tumor and liver tissue. Tumor control was performed by IV injection of blocking
Olaparib dose. Liver control was performed by injection of vehicle. Nuclear vs cytoplasmic
uptake was automatically detected using an ImageJ script to detect colocalization of
Hoechst (IV injected 5 minutes before extracting the organs) and PARPi-FL. Student t-test,
**p-value < 0.01, ***p-value < 0.001.
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fluorescent analogue of the same PARP1 inhibitor with comparable biodistribution and tumor
uptake after intravenous injection (Carlucci et al. 2015; Carney et al. 2017; Irwin et al. 2014;
Kossatz et al. 2017b; Salinas et al. 2015). PARPi-FL was injected intravenously (50 μg per mouse)
2 h before collecting the animals’ tumor and liver (Figure 23C, 25A). Organs were then sectioned,
and tissue sections digitalized. Hoechst (150 μL/mouse of 10 mg/mL) was used for nuclear
counterstaining. PARPi-FL accumulated in the nucleus of GBM cells as confirmed by colocalization with Hoechst signal. Livers were collected and imaged with an inverted confocal
microscope. PARPi-FL accumulation was observed in the cytoplasm of liver cells (Figure 23D),
suggesting that liver cells are protected from Auger-toxicity. In order to confirm this, we
performed an enzyme analysis in blood of mice injected with 123I-MAPi as compared to control.
1.09 ± 0.04 MBq were injected in n = 5 mice for the treated cohort, whereas the vehicle control

Figure 24 – In Vivo SPECT-CT of 123I-MAPi in Subcutaneous TS543 model. A. MIPS (top
row) and corresponding quantified coronal slices (bottom row) at selected time points after
intratumoral injection of 123I-MAPi with or without intravenous blocking with Olaparib.
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cohort (n = 5) received 150 μL of 30% PEG/PBS. No significant variations were observed in
treated mice compared with control (Figure 25B), confirming the very limited toxicity of the
injected molecule. These data suggest limited liver toxicity during hepatobiliary clearance, due to
the large distance of the Auger emitter from the DNA (Figure 25C).

Figure 25 – Subcellular Localization Study for 123I-MAPi. A. Tissue from mice injected
with PARPi-FL and Hoechst. PARPi-FL uptake was blocked in tumors by injection of 100fold excess dose Olaparib 1 h prior to injection of PARPi-FL. Liver control was performed
injecting vehicle IV. B. Liver enzyme analysis of 123I-MAPi treated mice (n = 5) and vehicle
control mice (n = 5). Grey band represents expected value range for healthy female mice.
C. A suggested mechanism of radiation protection for liver cells is that Auger radiation
specific toxicity depends on the isotope being in the proximity of the target DNA, which
doesn’t happen in these cells.
Imaging of an Orthotopic GBM Model Using 123I-MAPi.
To test 123I-MAPi in a more realistic model of GBM, we orthotopically implanted TS543
cells into the right brain hemisphere. This GBM model proved to be very consistent in growth and
take rate, as we monitored by MRI imaging of the head. 50,000 cells were injected at Week 0,
62

which resulted in rapid disease progression leading to animal death at Week 7 (Figure 26A). Based
on this data we decided to deliver

123

I-MAPi treatment at Week 3.

123

I-MAPi was injected

intratumorally using the same stereotactic coordinates as for tumor implantation. Animals were
then imaged at 1 h and 18 h post-treatment. Full body SPECT/CT images were acquired, showing
retention of 123I-MAPi in the tumor at 18 hours post-injection (Figure 26B and Figure 27A).

Figure 26 – TS543 Glioblastoma Stem-Cell Mouse Model and 123I-MAPi Efficacy. A. MRI
monitoring of TS543 xenograft disease progression. B. SPECT/CT imaging of GBM with
123
I-MAPi single injection. Images were taken at 18 h after local injection. T = tumor, Cl =
clearing organs. C. Kaplan-Meier curve of mice injected with 123I-MAPi (local single
injection 370 kBq - 1.11 MBq, n = 10) compared to vehicle injection (n = 12). Log-Rank
(Mantel-Cox) test, **p-value < 0.01. D. Cytology staining of untreated mice at Weeks 3 and
7 after tumor implantation and cytology staining and MRI imaging of treated mouse brain
at 14 weeks post implantation.
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Therapeutic Efficacy of 123I-MAPi in a GBM Mouse Model.
We monitored the clinical potential utility of

123

I-MAPi in treating GBM in the above

described orthotopic mouse model. 123I-MAPi-treated mice were then monitored daily, using Day
98 (the end of Week 14), measured from the day of xenografting, as the study endpoint. We
injected an intratumoral single dose
(0.37 – 1.11 MBq) of 123I-MAPi for
the treated cohort (n = 10) and the
same volume of vehicle for the
control cohort (n =12). Survival
data

confirmed

an

improved

survival for the 123I-MAPi treatment
cohort, with a median survival of 58
days as opposed to 40 days
observed for the control cohort.
Log-rank curve comparison showed
Figure 27 – In Vivo SPECT-CT of 123I-MAPi in Orthotopic
TS543 Model. A. Quantified coronal slices at 1 h and 18 h
post local injection of 123I-MAPi. 123I-MAPi was injected
value = 0.009 (Figure 26C, Table 2).
intratumorally using the same stereotactic coordinates as for
tumor implantation. The animal was imaged in a
Animals brains were imaged ex vivo
nanoSPECT/CT at the indicated time points post injection.
a significant difference, with p-

with H&E staining and in vivo with MRI showing a diffuse presence of cancer cells in vehicle
treated mice as opposed to the treatment (Figure 26D).
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Table 2 - Survival of Single Dose Treatment with 123I-MAPi.
n
Median surv. (days)
p-value†
IT injection vehicle
12
50
123
IT injection I-MAPi
10
58
** 0.0094
†
Log-Rank (Mantel-Cox) test.
Improved delivery of 123I-MAPi for clinical translation.
In clinics, to improve biodistribution toward a more effective targeted therapy, the
radiopharmaceutical can be administered directly into the tumor compartment. For brain tumors
this is achieved through intra-tumoral injection, intra-thecal injection, or convection enhanced
delivery (CED), an approach that elevates the injection pressure so as to impel the agent across the
BBB. To allow for clinical translation of 123I-MAPi, we first built a preclinical model of CED. We
implanted an ALZET® osmotic delivery pump with a subcutaneous catheter in tumor-bearing
mice. This delivered the content of the subcutaneous reservoir at a flow rate of 1 μL/h over the
course of approximately 100 h through a cannula connected to the mouse brain. Subcutaneous
reservoirs were filled with 100 μL of 123I-MAPi for the treatment cohort (n = 8) and with 100 μL
of vehicle for the control cohort (n = 8). Five days post-implantation, we surgically removed the
pumps, as per manufacturer instruction, and monitored mice survival. Kaplan-Meier survival plots
confirmed the therapeutic efficacy of 123I-MAPi: treated mice presented a median survival of 72 d
as opposed 48 d in the control cohort, a statistically significant difference of 50% (Log-rank pvalue = 0.0361, Figure 28A and Table 3). Dosimetry for the CED experiments (Figure 28B)
confirmed accumulation in the tumor with minimal absorbed dose to healthy organs not in direct
proximity to the implanted pump (Figure 28C). Importantly, while not feasible in a mouse model,
normal organ doses would be significantly reduced in a corresponding clinical scenario where the
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radionuclide reservoir would be external, shielded, and the administration performed over a shorter
timescale.
Table 3 - Survival of CED Dose Treatment with 123I-MAPi.
n
Median surv. (days)
p-value†
IT injection vehicle
8
48
IT injection 123I-MAPi
8
72
* 0.0361
†
Log-Rank (Mantel-Cox) test.

Figure 28 – Improved Delivery of 123I-MAPi with an in Vivo CED Model. A. Kaplan-Meier
survival study of pump implanted mice shows an improvement of survival of 123I-MAPi
treated mice (n = 8) when compared to control (n = 8). Treatment mice osmotic pumps were
loaded with 481 ± 111 kBq. Log-Rank (Mantel-Cox) test, *p-value < 0.05. B. Organ-level
and C. 3D dosimetry estimates calculated by Monte Carlo simulation for subcutaneous
pump administration. Equivalent doses assume the measured deterministic RBE of 48.4 for
123
I-MAPi tumor tissue and assume RBE of 1.0 elsewhere. T = tumor, P = pump.
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Intrathecal injection of 123I-MAPi for a further simplified clinical translation.
We then investigated a more broadly used and technically feasible brain drug delivery method for
delivering 123I-MAPi across the BBB. Tumor-bearing mice were injected with 50 μL of 123I-MAPi
intrathecally at 3 weeks after orthotopic tumor implantation. SPECT/CT imaging was performed
at 1 h post injection in order to visualize

123

I-MAPi accumulation in the brain (Figure 29A).

Imaging confirmed favorable pharmacokinetics and specific tumor uptake, suggesting intrathecal
delivery as a feasible technique for our small molecule. Unfortunately, this technique leads to
surgery-related high levels of stress in the mice model preventing us from being able to monitor
survival.

Discussion
In the present work, we show
the results for the first preclinical
characterization of an Auger-emitting
theranostic PARP inhibitor. We present
a

functioning

synthesis

of

workflow
a

stable

for
123

the

I-MAPi

compound which proved to be effective
in vitro at reducing the viability of
GBM cell lines. The lethality of

123

I-

MAPi suggests that the DNA is in range
of the Auger electrons when it is

Figure 29 – Translation Potential of 123I-MAPi. A.
SPECT/CT imaging of 123I-MAPi administered
intrathecally, 1 h post injection. T: tumor; I.S.: injection
site; G.B.: gallbladder; I: intestine; U.B.: urinary
bladder. B. We speculate that the different delivery
methods characterized can show clinical potential for a
reduced patient’s stress and improved tumor
accumulation. Biodistribution of 123I-MAPi in the
cytosol of non-target cells limits unspecific toxicity and
clinical side effects, preserving clearing organs.
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complexed with PARP1. It was further established that GBM cell death is induced through
radiogenic damage rather than PARP inhibition at these tracer levels.
In vivo studies with human tumor xenografts models also show 123I-MAPi drug treatment
efficacy. The 159 keV gamma emission of I-123 allowed for quantification of drug uptake in
tumor-bearing mice by SPECT/CT imaging. The isotope is ideal isotope for a proposed theranostic
PARPi clinical agent because of its widespread use in nuclear medicine for thyroid disorders
(Na123I) and pediatric tumors (123I-MIBG). Animal studies employing the non-radioactive drug
Olaparib show prolongation of blood pool clearance and blocked tumor uptake, proving 123I-MAPi
binding specificity.
To illustrate the potential advantages of clinical translation of

123

I-MAPi, and to better

illustrate the impact of Auger therapeutics, we looked at the agent’s potential subcellular
biodistribution. In vitro γ-H2AX analysis showed a significantly increased number of doublestrand breaks in cells treated with

123

I-MAPi when compared to

127

I-PARPi or vehicle control

(***p-value < 0.001, Kruskal-Wallis test, Figure 21D). Furthermore, by looking at the foci
morphology, it is possible to observe larger and more clustered foci in the

123

I-MAPi treated

samples as compared to spontaneously-induced and background foci (Figure 21A,B and C). In this
study, we did not notice any variation in the levels of PARP1 (green staining) as expected due to
a positive feedback loop of self-amplification of PARP1 expression (Kossatz et al. 2017a). For
this reason, we decided to not include a potential PARP1 amplification effect in the kinetic
modelling for dosimetry studies. We performed a colony formation assay to test efficacy of 123IMAPi in U251 cells. The obtained data shows a steep drop in survival, which was expected due to
the high-LET nature of Auger electrons. Comparison with EBIR allowed us to calculate the RBE
which corroborated, the potential of Auger-emitting molecules for targeted radiotherapy. This
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proved to be a significant improvement compared to a previously-published version of the
molecule,

131

I-PARPi, where the RBE of the emitted electron is considered to be significantly

lower. There has been a prior clinical trial I/II trial in which the therapeutic effects of an 131I-A33
(Welt et al. 1994) and an

125

I-A33 (Welt et al. 1996), an antibody targeting colon cancer, were

studied. I-125 is an Auger electron emitting radionuclide with comparable properties to I-123
(Howell 1992). This study showed that the maximum tolerated activity for
GBq/m2 (75 mCi/m2) in heavily pretreated patients, whereas for

125

131

I-A33 was 2.78

I-A33, bone marrow toxicity

was not seen after administered activities as high as 12.95 GBq/m2 (350 mCi/m2). In this study as
in the A33 trial, it is expected that the short-range emissions from I-123 will result in far lower
normal tissue toxicity (including dose limiting organs). In vivo, Olaparib-based PARP inhibitors
are cleared mainly via the hepatobiliary pathway (Carney et al. 2017) and the liver is therefore a
potential organ for Auger-specific radiotoxicity. In preparation for clinical translation of

123

I-

MAPi, we performed studies to investigate liver toxicity. We found near-exclusive extracellular
or perinuclear localization of 123I-MAPi in liver cells (i.e. the DNA of the liver parenchymal cells
is out of range of most of the emitted low-range Auger electrons) as shown with the fluorescent
analog PARPi-FL. This is in stark contrast to the observed nuclear accumulation of 123I-MAPi in
GBM cells (Figure 23C). The cytoplasmic liver accumulation is also corroborated by a liver
enzyme analysis we performed on injected mice. We did not find significant changes of enzyme
levels when compared to control mice (Figure 25B). The radiobiological effectiveness of Augeremitting compounds is critically dependent upon the proximity of the electron emitter to the
cellular DNA (Falzone et al. 2018; Royle et al. 2016). This distance dependent relationship for
double strand break production has been shown for I-125 (Humm and Charlton 1989). Cell-level
dosimetry analysis showed a noteworthy increase of cell sterilization as a function of absorbed
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dose with

123

I-MAPi in comparison to external photon irradiation, resulting in high estimates of

relative biological effectiveness and suggesting that intranuclear radiation dose from PARP1bound 123I-MAPi is nearly 50 times as potent as that from externally directed photons. The dose
was calculated to the tumor cells using PARaDIM v1.0, a Monte Carlo method, using as input the
time-integrated activity coefficients from measured data. These cellular dose estimates were
confirmed against standard cellular methods from MIRDcell (Vaziri et al. 2014). We do, however,
caution that these cell dose and RBE estimates strongly depend on the measured cell size, end
point, reference radiation, and model assumptions. Based on the small literature on the potential
use of I-123 labeled pharmaceuticals for therapy (Li et al. 2004; Mariani et al. 1996) (although this
could be different in using I-123 labeled PARP agents), projected in-human dose could start from
an imaging dose of 8 mCi and collect biodistribution data for dosimetry calculations prior to guide
a Phase I study in patients.
To force a more favorable biodistribution toward tumor-targeting in clinical targeted
radionuclide studies directed at brain tumors, investigators have proposed intra-tumor injection
(Zalutsky et al. 2008), intrathecal injection (Kramer et al. 2018) and more recently convection
enhanced delivery (CED) to administer the antibody across the BBB and into tumor tissue – e.g.
to treat diffuse intrinsic pontine glioma (Souweidane et al. 2018). The above approaches have
shown the ability to significantly improve the ratio of the radiation dose delivered to tumor relative
to normal dose-limiting tissues. Many clinics do have the capability to perform intratumoral and
intrathecal injection with or without a CED system (Kramer et al. 2007; Kramer et al. 2010;
Kramer et al. 2015). This delivery method, albeit not simple, is becoming more widely used as
more patients present with, tumors growing behind the blood-brain barrier; a consequence of the
improved efficacy of chemotherapy for the treatment of vascular accessible disease. To emulate
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these studies in a pre-clinical setting, we adopted an orthotopic GBM model in mice and performed
a local injection of 123I-MAPi using an intratumoral osmotic pump delivery system. This system
allowed for constant and prolonged delivery of the drug directly to the tumor and its
microenvironment. Dosimetry estimates based on imaging, tissue specimen counting, and
treatment response shown by Kaplan-Meier survival data are suggestive of the high potential
clinical impact of this approach.
CEDs and Ommaya reservoirs are emerging as effective chemotherapy and targeted
radionuclide delivery methods for patients with previously inaccessible metastatic disease. We
have developed a method to perform CED injection of novel radiopharmaceuticals in pre-clinical
models of cancer. We also performed intrathecal injection which would allow tumor imaging and
therapy in clinical settings. This technique is routinely performed in most hospitals for
chemotherapy drug delivery and allows clinicians to access the brain without opening the patient’s
skull. SPECT/CT imaging can visualize and quantify radiolabeled drug uptake in tumor and its
dispersion throughout the tissues of the body. We have demonstrated this capability with a newly
developed theranostic agent, 123I-MAPi. We have shown that it can access the brain when injected
intrathecally and using the intratumoral osmotic pump delivery system. While the favorable
pharmacokinetics was accompanied by stressful side-effects in some mice (on account of the
comparatively small volumes of the murine skull), this has not been, nor is it expected to be, a
limiting factor for human studies.

Conclusion
To conclude, we characterized the first Auger-emitting PARP inhibitor in vivo which
presented promising therapeutic results in a pre-clinical glioma model. The physical properties of
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Auger emission, paired with the biological distribution of a PARP inhibitor, make it possible to
speculate that a dose escalation in patients could achieve high tumoricidal doses with limited
normal tissue toxicity. The 159 keV gamma ray emitted is at the sweet spot for gamma camera
imaging in patients and will allow for monitoring of treatment delivery across the BBB,
redistribution, and precise dose evaluation, leading to truly personalized treatment plans (Figure
29B). 123I-MAPi has the potential to be a new and potent clinical agent for the treatment of brain
tumors when used in conjunction with new intrathecal/CED administration methods.

Materials And Methods
General
Sodium [123I]iodide in 0.1 N NaOH with a specific activity of 7.14 x107 GBq/g was
purchased from Nordion (Ottawa, Canada). 4-(4-fluoro-3-(4-(3-iodobenzoyl)piperazine-1carbonyl)benzyl)phthalazin-1(2H)-one was synthesized as described previously (Menear et al.
2008). Olaparib (AZD2281) was purchased from LC Laboratories (Woburn, MA). PARPi-FL was
synthesized as previously described (Irwin et al. 2014; Reiner et al. 2012). Water (>18.2 MΩcm-1
at 25 °C) was obtained from an Alpha-Q Ultrapure water system (Millipore, Bedford, MA) and
acetonitrile (AcN) as well as ethanol (EtOH) were of HPLC grade purity. Sterile 0.9% saline
solution (Hospira, Lake Forest, IL) was used for all in vivo injections. High performance liquid
chromatography (HPLC) purification and analysis was performed on a Shimadzu UFLC HPLC
system equipped with a DGU-20A degasser, an SPD-M20A UV detector, a LC-20AB pump
system, and a CBM-20A Communication BUS module. A LabLogic Scan-RAM radioTLC/HPLC-detector was used to detect activity. HPLC solvents (Buffer A: Water, Buffer B: AcN)
were filtered before use. Purification of 2,5-dioxopyrrolidin-1-yl 3-(iodo-123I)benzoate was
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performed with Method 1 (flow rate: 1 mL/min; gradient: 15 min 5-95% B; 17 min 100% B; 20
min 100%-5% B); QC analysis was performed with Method 1. Method 1 was performed on a
reversed phase C18 Waters Atlantis T3 column (C18-RP, 5 μm, 6 mm, 250 mm). Purification of
the final product was performed on a C6 Waters Spherisorb Column (C6, 5 µm, 4.6 mm × 250
mm) with Method 2 (flow rate: 1.5 mL/min; isocratic: 0-30 min 35% B.)

Cell Culture
The human glioblastoma cell line U251 was kindly provided by the laboratory of Dr.
Blasberg (MSK, New York, NY). Cells were grown in Eagle’s Minimal Essential Medium
(MEM), 10% (vol/vol) heat inactivated fetal bovine serum, 100 IU2 penicillin, and 100 μg/ml
streptomycin, purchased from the culture media preparation facility at MSK (New York, NY).
TS543 cells are a patient-derived glioblastoma stem line kindly provided by the laboratory of Dr.
Mellinghoff (MSK, New York, NY). These cells were grown in suspension in NeuroCultTM NSA Proliferation Kit with proliferation supplement (StemCell Technologies, Cat 05751), 20 ng/mL
Recombinant Human Epidermal Growth Factor (EGF) (StemCell Technologies, Cat 02633), 10
ng/mL Recombinant Human Basic Fibroblast Growth Factor (Bfgf) (StemCell Technologies, Cat
02634), 2 μg/mL Heparin (StemCell Technologies, Cat 07980), 1× antibiotic-antimicotic (Life
Technologies Gibco, Cat 15240-062), 2.5 mg/mL Plasmocin (InvivoGen, Cat ant-mpp). All cells
were tested for mycoplasma contamination.

Immunofluorescence
Cells were plated on a coverslip slide on the bottom of a 6-well plate and incubated
overnight.

123

I-MAPi,

127

I-PARPi, or vehicle control were added to the media and cells were
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returned to the incubator overnight. Cells were then fixed in 4% paraformaldehyde/PBS,
permeabilized and stained with anti γ-H2AX antibody (*****) and anti PARP1 antibody (****).
DAPI was used to localize nuclei. Coverslips were mounted on slides for microscopy imaging.

Immunoblotting
Cells were lysed in RIPA (Thermofisher Scientific, cat #89900) buffer containing protease
inhibitor at 4 °C. Lysates were run on an SDS-Page gel (BioRad). Bound antibodies were detected
by developing film from nitrocellulose membranes exposed to chemiluminescence reagent
(#34077, Thermo Scientific). PARP1 primary antibody (Santa Cruz #sc-7150, 0.2 μg/mL) and goat
anti-rabbit IgG-HRP secondary antibody (1:10000 dilution, sc-2004, SantaCruz). An anti-β-actin
antibody (Sigma #A3854, 1:1000) was used as loading control.

Synthesis of 123I-MAPi
123

I-MAPi was obtained similar to synthetic procedures reported before (Jannetti et al.

2018). Firstly, 2,5-dioxopyrrolidin-1-yl 3-(iodo-123I)benzoate was obtained by adding Nsuccinimidyl-3-(tributylstannyl) benzoate (250 μg, 0.5 μmol) in 10 μL of AcN to a solution
containing methanol (40 μL), chloramine T (9 μg, 32 nmol), acetic acid (3 μL) and

123

I-NaI in

NaOH 0.1 M (2.5 mCi). After the reaction solution was driven for 20 min at room temperature,
the reaction was purified by HPLC (Method 1), and 2,5-dioxopyrrolidin-1-yl 3-(iodo-123I)benzoate
at 15.1 min. The collected purified fraction was concentrated to dryness in vacuum, reconstituted
in a solution of 80 μL AcN and added to a solution of 4-(4-fluoro-3-(piperazine-1carbonyl)benzyl)phthalazin-1(2H)-one (0.3 mg, 0.9 μmol) in 20 μL DMSO, N,N,N’,N’Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) (0.3 mg, 0.8 μmol)
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in 20 μL DMSO, 4-Dimethylaminopyridine (DMAP) (0.1 mg, 0.8 μmol) in 20 μL DMSO and 10
μL triethylamine. The reaction mixture stirred in an Eppendorf ThermoMixer® for 2 h at 65 °C
(500 rpm). Afterwards, the reaction mixture was injected and purified by HPLC (Method 2) and
123

I-MAPi was collected at RT = 25.5 min (RY > 70%; RP > 99%) and concentrated to dryness

under vacuum. 123I-MAPi was formulated with 30% PEG300 / 70% saline (0.9% NaCl) for both
in vitro and in vivo assays. Co-elution with nonradioactive

127

I-PARPi reference compound

confirmed the identity of the radiotherapeutic. 123I-MAPi was synthesized with molar activity of
3.93 ± 0.10 GBq/μmol.

Internalization Assay
Uptake of 123I-MAPi was tested in vitro (3 replicates). 5×105 U251 cells were plated 24h
prior to the experiment (n = 3). Media was changed and 1 h later 3.7 kBq of 123I-MAPi were added
to the cells. For blocking, cells were incubated with a 100-fold molar excess of Olaparib 1 h before
adding 123I-MAPi. Media was removed, and cells were washed with PBS and lysed (1 M NaOH)
at different time points. The lysate was collected, and uptake was determined by radioactivity on
a gamma counter.

Viability Assay
U251 GBM cells were incubated with 0 – 296 kBq of

123

I-MAPi or equivalent dose of

Olaparib overnight and then washed and incubated for 4 d in normal media (3 replicates, n = 3
each). Viability was determined by AlamarBlue assay as indicated by the manufacturer.

75

Colony Formation Assay
Colony formation assay (CFA) was performed using U251 cells as previously described
(Tiwana et al. 2015) (n = 3). Colony formation was measured at two weeks post

123

I-MAPi

treatment and compared to EBIR. Cells were treated adding 0 – 23 kBq of compound in each well.
Colony count was normalized on plating efficiency at 0 kBq for each treatment. External beam
irradiation (EBIR) was performed using a Shepperd Irradiator Cs-137 at Memorial Sloan Kettering
Cancer Center, New York, NY, USA. Radiobiological parameters of the linear-quadratic model
were determined via non-linear regression within GraphPad software, and relative biological
effectiveness was determined by interpolation, using 37% survival as the end-point.

Animal Work
All in vivo experiments were performed with female athymic nude CrTac:NCr-Fo mice
were purchased from Taconic Laboratories (Hudson, NY) at age 6-8 weeks. During subcutaneous
injections, mice were anesthetized using 2% isoflurane gas in 2 L/min medical air. 1×106 TS543
cells were injected in the right shoulder subcutaneously in 150 μL volume of 50% media/matrigel
(BD Biosciences, San Jose, CA) and allowed to grow for approximately two weeks until the tumors
reached about 8 mm in diameter (100 ± 8 mm3). For intravenous injections, the lateral tail vein
was used. Mice were warmed with a heat lamp, placed in a restrainer, and the tail was sterilized
with alcohol pads before injection. For orthotopic injections, TS543 cells (5×105 cells in 2 μL
growth media) were injected 2 mm lateral and 1 mm posterior to the bregma using a Stoelting
Digital New Standard Stereotactic Device and a 5 μL Hamilton syringe and allowed to grow for
three weeks before treatment. All mouse experiments were performed in accordance with protocols
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approved by the Institutional Animal Care and Use Committee of MSK and followed National
Institutes of Health (NIH) guidelines for animal welfare.

SPECT/CT Imaging
SPECT/CT scans were performed using a small-animal NanoSPECT/CT from Mediso
Medical Imaging Systems (Budapest, HU). For subcutaneous TS543 xenografts, 123I-MAPi (2.3 ±
0.5 MBq in 20 μL 30% PEG300 in 0.9% sterile saline) was administered intratumorally as single
injection. At chosen time points post injection, the mice were anesthetized with 1.5-2.0%
isoflurane (Baxter Healthcare) at 2 mL/min in oxygen and SPECT/CT data was acquired for 60
min.
For orthotopic TS543 tumor-bearing mice 123I-MAPi (614.2 kBq in 5 μL 30% PEG300 in
0.9% sterile saline) was injected intracranially using the same coordinates as for tumor cell
injection (2 mm lateral and 1 mm posterior to the bregma using a Stoelting Digital New Standard
Stereotactic Device and a 5 μL Hamilton syringe). At chosen time points post injection, the mice
were anesthetized with 1.5-2.0% isoflurane (Baxter Healthcare) at 2 mL/min in oxygen.
SPECT/CT data was collected for 60 min.

Ex vivo Biodistribution for Intratumoral Administration Route
Biodistribution studies were performed in subcutaneous TS543 xenograft-bearing mice.
Mice were randomized and divided in two groups (blocked and unblocked, ntotal = 6) and

123

I-

MAPi was administered intratumorally (average injected activity 1.702 ± 0.629 MBq in 20 μL,
30% PEG300 in 0.9% sterile saline). The blocked group was pre-injected (1 mg/mouse in 100 μL
30% PEG300 / 70% NaCl 0.9%) 60 min prior to treatment with Olaparib (100mM stock in
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DMSO). Mice were sacrificed by CO2 asphyxiation at 18 h post injection and counted in a
WIZARD2 automatic g-counter (PerkinElmer, Boston, MA). Uptake was expressed as a percentage
of injected dose per gram (% ID/g) using the following formula: [(activity in the target organ/grams
of tissue)/injected dose].

Survival Studies
Mice were inoculated orthotopically at Week 0 with TS543 cells (5×105 cells in 2 μL
growth media). Cells were injected 2 mm lateral and 1 mm posterior to the bregma using a
Stoelting Digital New Standard Stereotactic Device and a 5 μL Hamilton syringe and allowed to
grow for three weeks before treatment. At Week 3 mice were randomly grouped into cohorts, and
intratumorally injected with

123

I-MAPi or 30% PEG300 in 0.9% sterile saline vehicle using the

same stereotactic coordinates as for tumor implantation. Mice were monitored daily thereafter.
Study endpoint was determined based on animals’ sign of discomfort, pain, or significant weight
loss.

Orthotopic CED Model
ALZET® Osmotic Pumps were implanted subcutaneously into the mice to slowly deliver
an infusion into the brain using the same coordinates as for the tumor cell injection as previously
described (Jannetti et al. 2018). Control mice received an ALZET® Osmotic Pump Model 1003D
with Brain Infusion Kit 3 containing 30% PEG/PBS vehicle. Treatment mice received 123I-MAPi
(average pump activity 481 ± 111 kBq in 100 μL, 30% PEG300 in 0.9% sterile saline. Delivery
flow 1 μL/h, over 5 d). Pumps were surgically removed 5 d post implantation and mice monitored
daily thereafter.
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Intrathecal Injection
Brain-tumor-bearing mice were anesthetized and injected in the intrathecal space (injection
site from L3/5 or L4/5 to prevent spinal cord injury) 2.0 MBq of 123I-MAPi in 50 μL 30% PEG300
in 0.9% sterile saline 123I-MAPi were injected and the mice imaged 1 h post injection.

Hematoxylin–Eosin (H&E) Staining
Brains were collected from mice at the time of death. The collected brains were embedded
in Tissue-Tek O.C.T. compound (Sakura Finetek, Torrance, CA), flash-frozen in liquid nitrogen
and cut into 10 μm sections using a Vibratome UltraPro 5000 Cryostat (Vibratome, St. Louis,
MO). Sections were subsequently subjected to H&E staining for morphological evaluation of
tissue pathology.

Liver Enzymes Analysis
Animals (n = 5/cohort) were injected systemically with either 123I-MAPi or Vehicle control.
After 24 hours blood was collected via retro-orbital bleeding. Enzymes levels were determined by
the Antitumor assessment core at Memorial Sloan Kettering Cancer Center.

Dosimetry
Estimation of Time-Integrated Activities from Nuclear Uptake.
In vitro labeling experiments demonstrated saturable uptake of 123I-MAPi over a short time
scale of ~1 h, and minimal uptake in the cytoplasm vs. cell nuclei, and therefore, uptake into the
cell nuclei was assumed to be instantaneous. Further, the percentage of applied activity
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accumulating in the cells (nuclei) was assumed to be proportional to the cell number. As the
physical half-life of I-123 is short (13.2 h) in comparison to the doubling time for this cell line
(~24 h), no cell division was assumed to have taken place during the dose accumulation period.
The time-integrated activity for the whole system (comprised of the cells and surrounding media
together) Ãtot was calculated as 1.44 × A0 × t1/2 = 1.58E9 Bq∙s, and the time integrated activities
for the cell nuclei (all nuclei collectively) and surrounding media were calculated as the product
of Ãtot and the respective fraction of activity present in each component at saturation (ÃNuclei = Ãtot
× 0.0262%; ÃMedia = Ãtot × 99.974%). The time-integrated activity in the cell nuclei was assumed
to be distributed uniformly across the all cell nuclei in the population.

Construction of a Phantom for Cell-level Absorbed Dose Calculation.
A surface-mesh cell phantom was constructed in the 3D modeling software Blender
(www.blender.org). Individual cells and nuclei were modeled as concentric spheres using the
subvision-level 2 icosphere geometric primitive, using the average radii for the nucleus and cell
surface as-measured via microscopy. The cell models were semi-randomly arrayed in a monolayer
(~800 total cells) in the x-y plane using a combination of Blender’s array, intersection, and noise
texture-based displacement modifiers, and were positioned at the base of a cylinder representing
the surrounding media. Finally, a 6 well culture plate was modeled to contain the previous
structures. The completed phantom (Figure 22A) was converted to tetrahedral mesh format using
TetGen, and tetrahedron region labels were re-assigned using an in-house Python program. Finally,
the tetrahedral phantom was imported into the PHITS-based dosimetry software PARaDIM, for
absorbed dose calculations.

80

Determination of Relative Biological Effectiveness (RBE).
Dose-response curves were fit via non-linear regression in GraphPad software, with the
linear-quadratic (L-Q) model viz: S = exp[-(αD + βD2)], where S is the surviving fraction, D is the
absorbed dose to the cell nuclei, and α and β are radiosensitivity coefficients parameterize the total
logarithmic dose response into linear and quadratic components, respectively (Figure 22B). For
123

I-MAPi, only the linear component was considered (i.e. β was constrained to zero). Each dose

response curve was interpolated to obtain the respective dose corresponding to a 37% survival
end-point, D37, and the RBE computed as D37,EBIR/D37,I-123 (Table 1).

Estimation Of Time-Integrated Activity Coefficients In Mouse Organs.
Radiation dose estimates for osmotic pump-based intratumoral administration of

123

I-

MAPi were obtained under the assumption that biological clearance kinetics of a small impulse of
123

I-MAPi are equivalent to those of

131

I-PARPi administered as a single bolus intratumoral

injection, and further that the clearance kinetics are not concentration-dependent. Under these
assumptions the activity 𝐴(𝑟h , 𝑡) (MBq) of 123I-MAPi in organ S is given by:
𝐴(𝑟h , 𝑡) = 𝐴̇(𝑡) ∗ 𝑎′(𝑟h , 𝑡)

Eqn. 7

where ∗ is the convolution operator, 𝐴̇(𝑡) is the rate of administration (MBq/h), and 𝑎′(𝑟h , 𝑡) is the
time-dependent fraction of injected activity of an impulse of

123

I-MAPi in organ S (i.e. that of a

single bolus). In the case that the dose integration period 𝑇m is taken as infinity (the usual case),
the time-integrated activity coefficient for the present case (slow infusion given by 𝐴̇(𝑡)) is
equivalent to the case of a single bolus injection. Thus, time-integrated activity coefficients for
mouse organs were calculated by applying the appropriate decay factor for I-123 to previouslyobtained organ time-activity data (Jannetti et al. 2018) for intratumorally-injected 131I-PARPi, and
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performing trapezoidal integration of the adjusted data for each organ (Table 4). Clearance after
the last measured time point was assumed to occur via radioactive decay only.

Estimation Of Time-Integrated Activity Coefficient For Osmotic Pump Contents.
Under the assumption that the 123I-MAPi is homogeneously distributed within the osmotic
pump contents, which occupy an initial volume 𝑉8 (µL) and are injected at a constant volumetric
flow rate 𝜅 (µL/h), the activity of the pump contents 𝐴(𝑝𝑢𝑚𝑝, 𝑡) can be expressed as (1):
e

g0

𝐴(𝑝𝑢𝑚𝑝, 𝑡) = 𝐻 U gf − 𝑡X ∙ 𝐴8 U1 − e X 𝑒 bc0

Eqn. 8

f

where 𝑡 is the time post-implantation, 𝐴8 is the initial activity in the implanted pump, and
𝐻(𝑉8 ⁄𝑘 − 𝑡) is a Heaviside function shifted in time by 𝑉8 ⁄𝑘 (i.e. the time the pump becomes
empty).
The activity injected 𝐴8,7rs (𝑡) can be expressed as:
g.

g.

𝐴8,7rs (𝑡) = 𝐻(𝑉8 ⁄𝜅 − 𝑡) ∙ cef a1 − 𝑒 bc0 d + 𝐻(𝑡 − 𝑉8 ⁄𝜅 ) ∙ cef a1 − 𝑒 bcef⁄g d
f

f

Eqn. 9
We define the time-integrated activity coefficient for the pump contents as normalized to the
activity injected (i.e. delivered through the cannula):
E

𝑎t(𝑝𝑢𝑚𝑝, 𝑡) =

∫f .(6uv6,0)-0

Eqn. 10

./wx (0)

which for 𝑡 = 𝑇m → ∞ is:
cgbg{ce

f
𝑎t(𝑝𝑢𝑚𝑝) = cgaB D|f⁄} b~d
−

gbcef

Eqn. 11

cg

The manufacturer specified values for 𝜅 (1 µL/h) and 𝑉8 (100 µL) were used for estimation of
𝑎t(𝑝𝑢𝑚𝑝) (Figure 28B,C, and Table 4).
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Table 4 - Time-Integrated Activity Coefficients Estimated for Intratumoral Administration
123

Organ or Region

I-MAPi via Osmotic Pump.
Time-integrated

activity

coefficient (MBq*h/MBq)
Intestines

0.399

Liver

0.208

Pancreas

0.000886

Stomach contents

0.0117

Heart contents

0.00536

Heart wall

0.00527

Lungs

0.00640

Brain

0.000946

Thyroid

0.000699

Skeleton

0.0597

Tumor

0.0597

Kidneys

0.00617

Remaining organs

0.139

123

81.5

I-MAPi solution (pump contents)

Osmotic pump (container portion)

0

Construction Of A CT-Derived Phantom For Dose Calculation.
A computed tomography (CT) scan of a mouse bearing an osmotic pump implanted over
the left shoulder was acquired on a NanoSPECT/CT device from Mediso Medical Imaging
Systems (Figure 25C). CT scans were reconstructed with an isotropic voxel size of 0.147 × 0.147
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× 0.147 mm using a Feldkamp cone-beam filtered back-projection algorithm (Mediso Ltd.). A
combination of manual and semi-automatic segmentation techniques were used to define the
osmotic pump, tumor, and major organs within 3D Slicer 4.10 (www.slicer.org); the segments
were subsequently converted to triangulated polygonal mesh. Within the mesh-editing software
Blender (www.blender.org), the polygon count of each mesh was reduced using an edge-collapse
decimation modifier (ratio 0.05-0.10), and small modifications made to correct for any
overlapping/non-manifold geometry. Thin wall structures of select organs (e.g. stomach, bladder)
were modeled by applying a vertex offset modifier to the corresponding structure defined
previously via segmentation. Finally, all surface meshes were merged, exported, and converted to
a tetrahedral mesh using TetGen (Si 2015). Following definition of the phantom region
information (region name, composition, etc.) using an in-house python program, the completed
phantom was imported into the PHITS-Based Application for Radionuclide Dosimetry in Meshes
(PARaDIM v1.0).

Absorbed Dose Calculation In Paradim.
Absorbed doses were calculated with PARaDIM v1.0 using time-integrated activity
coefficients given in Table 4. 1×108 total histories were simulated via PHITS on a HP Z8
workstation (3.6 GHz Intel Xeon 5122 processor, Windows 10 OS, single core calculation). The
default settings for physical models and energy cutoff (1 keV for electrons and photons) were used.
The material surrounding the phantom was defined as void. An isotropic voxel resolution of 1.0
mm was used for 3D dose calculation.
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CHAPTER FOUR – Alpha Emitter Radiotherapy in a Small Cell Lung Cancer Model

Introduction
Small Cell Lung Cancer has a 5-year survival rate less than 10%. Presently, there are no
highly-targeted radiotherapeutic for this extremely lethal disease (Byers et al. 2012). Poly(ADPribose)Polymerase 1 (PARP1) is a ubiquitous nuclear protein that is over-expressed in several
neoplasia, including small cell lung carcinomas (Byers et al. 2012). Moreover, radiotherapy is
integral to standard of care in treatment of many cancers, especially metastatic and inoperable
tumors. PAPR1 has been shown to be a viable target for radiotherapeutic small molecules in
several preclinical models (Jannetti et al. 2018; Makvandi et al. 2019; Pirovano et al. 2019; Reilly
et al. 2018; Salinas et al. 2015). A successful PARP1-targeted radiotherapeutic would induce DNA
damage and apoptosis in cancer cells, without inducing significant damage to surrounding healthy
tissue. We hypothesize that this could be accomplished by labeling with the short-range (55-80
μm) alpha emitter, astatine-211 (Vaidyanathan and Zalutsky 2008). Capitalizing on established
synthetic methods and a highly targeted drug scaffold we have taken the first steps in developing
a PARP1-targeted alpha-emitting radiotherapy.

Results
Synthesis
211

At-PARPi was synthesized using similar synthetic methods published previously

(Jannetti et al. 2018; Pirovano et al. 2019; Pozzi and Zalutsky 2007; Zalutsky et al. 2001). The
structure of 211At-PARPi is based on previously evaluated and published iodinated versions of the
modified olaparib scaffold (Jannetti et al. 2018; Pirovano et al. 2019). Radioactive 2,5-
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dioxopyrrolidin-1-yl 3-(astato-211At)benzoate was conjugated to the 4-[[4-Fluoro-3-(piperazine-1carbonyl)phenyl]methyl]-2H-phthalazin-1-one scaffold in good radiochemical yield (33%) and
with 99% radiochemical purity. Molar activity has been calculated as 2.98 ± 0.96 GBq/μmol
(Figure 30).

Figure 30 – Synthesis, Yield, and Purity. A. Synthesis scheme of 211At-PARPi. (a) 211At, NChlorosuccinimide, AcOH, MeOH, 20 m, RT; (b) HBTU, DMAP, DMSO, Et3N, ACN, 2 h, 65
°C; 33% RCY, 99% RCP. B. Radiotrace of 2,5-dioxopyrrolidin-1-yl 3-(astato-211At)benzoate;
75% RCY, 95% RCP. C. Radiotrace of 211At-PARPi; 33% RCY, 99% RCP, AS: 4.37 ± 0.96
GBq/mg, AM: 2.98 ± 0.96 GBq/μmol.
Choice of Model
JHU-LX22 cells were chosen due to the elevated levels of PARP1 expression (Figure 31A).
Previous studies with the fluorinated version of the modified olaparib scaffold showed favorable
target engagement (Carney et al. 2018). Specific uptake of 211At-PARPi in JHU-LX22 cells was
inhibited by incubating cells with a 50× molar excess of olaparib 1 hour prior to incubation with
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211

At-PARPi. Uptake was measured at 4.19 ± 1.38 %Uptake/106 Cells compared to blocked group

at 1.89 ± 1.25 %Uptake/106 Cells (Figure 31B).

Figure 31 – In Vitro Evaluation.. A. Western blot assay for PARP1 enzyme and 𝛽-actin control
in squamous cell carcinoma, glioblastoma, and small-cell lung cancer. B. LX22 cell line treated
with 211At-PARPi and pretreatment with molar excess olaparib. p = 0.0367. C. Sub-cellular
fractionation of 211At-PARPi in U251 and LX22 cell lines after four-hour incubation. D.
Comparison of halogenated PARP inhibitors in LX22 cell line after four-hour incubation.
Cellular Distribution
Subcellular protein fractionation enables the segregation of intracellular proteins from five
cellular compartments of cultured cells that have been subject to drug treatment or other
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experimental conditions. Proteins from each compartment are isolated in the supernatant of cells
lysates that have been incubated with unique extraction buffers and separated by centrifugation.
This process is repeated for protein isolation from each subsequent cellular compartment, allowing
us to determine the subcellular distribution of 211At-PARPi after a one hour incubation in the JHULX22 and U251-MG cells at four hours (Figure 31C). Nuclear uptake in JHU-LX22 cells was
significantly higher than any other compartment (Table 5). Distribution of 211At-PARPi in U251MG cells did not show a significant difference nuclear uptake and membrane uptake (Table 6,
Figure 31B). No significant difference was found in subcellular distribution between 211At-PARP
and 18F-PARPi in JHU-LX22 cells, except in the cytoskeleton (p = 0.0010, Figure 31D).

Table 5 – Subcellular Distribution of 211At-PARPi in JHU-LX22 Cells.
Mean Diff.

95.00% CI of diff.

Adjusted
P Value

Summary

membrane vs. cytoplasm

4.033

-6.825 to 14.89

0.9485

ns

membrane vs. cytoskeleton

5.767

-5.092 to 16.63

0.6904

ns

membrane vs. nucleus

-14.47

-25.33 to -3.608

0.0045

**

membrane vs. chromatin-bound

0.6667

-10.19 to 11.53

>0.9999

ns

cytoplasm vs. cytoskeleton

1.733

-9.125 to 12.59

>0.9999

ns

cytoplasm vs. nucleus

-18.50

-29.36 to -7.641

0.0003

***

cytoplasm vs. chromatin-bound

-3.367

-14.23 to 7.492

0.9847

ns

cytoskeleton vs. nucleus

-20.23

-31.09 to -9.375

<0.0001

****

cytoskeleton vs. chromatin-bound

-5.100

-15.96 to 5.759

0.8153

ns

nucleus vs. chromatin-bound

15.13

4.275 to 25.99

0.0029

**

JHU-LX22
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Table 6 - Subcellular Distribution of 211At-PARPi in U251-MG Cells.
Mean Diff.

95.00% CI of diff.

Adjusted
P Value

Summary

membrane vs. cytoplasm

13.90

3.041 to 24.76

0.0066

**

membrane vs. cytoskeleton

12.83

1.975 to 23.69

0.0136

*

membrane vs. nucleus

1.100

-9.759 to 11.96

>0.9999

ns

membrane vs. chromatin-bound

8.433

-2.425 to 19.29

0.2162

ns

cytoplasm vs. cytoskeleton

-1.067

-11.93 to 9.792

>0.9999

ns

cytoplasm vs. nucleus

-12.80

-23.66 to -1.941

0.0139

*

cytoplasm vs. chromatin-bound

-5.467

-16.33 to 5.392

0.7494

ns

cytoskeleton vs. nucleus

-11.73

-22.59 to -0.8747

0.0283

*

cytoskeleton vs. chromatin-bound

-4.400

-15.26 to 6.459

0.9138

ns

nucleus vs. chromatin-bound

7.333

-3.525 to 18.19

0.3785

ns

U251-MG

Biodistribution
211

At-PARPi was intravenously injected at into JHU-LX22 tumor bearing mice. Tumor

uptake was significant compared to muscle uptake at 1 hour and 3 hours post injection (p = 0.0011
and 0.0041, respectively). Tumor to muscle uptake ratio at 1-hour post injection is 4.49 ± 0.89
and 4.40 ± 1.26 at 3 hours post injection (Figure 32). There is no significant difference between
tumor uptake and other collected organs at 6 hours and beyond.

Discussion
A two-step synthesis was implemented, where 2,5-dioxopyrrolidin-1-yl 3-(astato211

At)benzoate starting material has been synthesized and published previously (Zalutsky et al.

2001). Moving to cartridge purification reduced reaction time. JHU-LX22 cells have PARP1
expression comparable to U251-MG cells. We believe this preclinical model is more
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translationally
relevant

than

glioblastoma, as alpha
emitters

will

inherently induce offtarget cell death at the
tumor

margins.

Finding a molar excess
of

olaparib

could

Figure 32 – In Vivo Biodistribution. A. Subcutaneous LX22 xenograft inhibit approximately
bearing athymic mice were administered 5 μCi of 211At-PARPi
intravenously. Ex vivo biodistribution and gamma counting performed at half of the activity can
1, 3, 6, and 18 hours post injection. n=5 per time point.
possibly be explained
by non-specific uptake of 211At-PARPi seen in the subcellular fractionation experiment where 44.1
± 8.8 % of drug uptake is in the nuclear compartment, compared to 20.5 ± 3.1 % perinuclear
activity and 15.1 ± 4.2 membrane activity. The only significant difference in fractionation between
211

At-PARPi and

18

F-PARPi is in the perinuclear compartment (p < 0.05). Using muscle as an

indicator of non-specific uptake, we find a significant difference between tumor and muscle uptake
up to 3 hours, but no longer at 6 hours. A possible explanation for this data is the dissociation of
astatine-211 from the small molecule, a known issue with astatinated compounds. An indication
of this is the high uptake in both thyroid and stomach organs, where free astatine accumulates.
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Conclusion
We have synthesized an astatine-211 labeled PARP inhibitor in high specific activity in
favorable yields. Preliminary in vitro experiments indicated target specificity for PARP1 in an
JHU-LX22 cell line model of small-cell lung cancer through blockable uptake as well as nuclear
presence. Cellular distribution remains consistent between the fluorinated and astatinated PARPis.
Ex vivo gamma counting of our drug shows tumor uptake and retention up to 18 hours post
injection. We find these results warrant further investigation of the potential for an 211At-labeled
compound as a targeted radiotherapeutic for PARP1 over-expressing cancers.

Methodology
General
All chemicals and solvents were purchased from Sigma Aldrich unless otherwise noted.
Olaparib (AZD2281) was purchased from LC Laboratories (Woburn, MA). Water (>18.2 MΩcm1

at 25 °C) was obtained from an Alpha-Q Ultrapure water system (Millipore, Bedford, MA) and

acetonitrile (AcN) as well as ethanol (EtOH) were of HPLC grade purity. Sterile 0.9% saline
solution (Hospira, Lake Forest, IL) was used for all in vivo injections. High-performance liquid
chromatography (HPLC) was performed using a Beckman Gold HPLC system equipped with a
Model 126 programmable solvent module, a Model 166 NM variable wavelength detector, and a
ScanRam RadioTLC scanner/HPLC detector combination (LabLogic; Brandon, FL, USA). HPLC
data were acquired and processed using the Laura software (LabLogic). HPLC solvents (Buffer
A: Water, Buffer B: AcN) were filtered before use. Purification of 2,5-dioxopyrrolidin-1-yl 3(astato-211At)benzoate was performed by Sep-Pak C18 Plus Light Cartridge (WAT023501).
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Purification of the final product was performed on a C18 Waters Atlantis T3 column (C18-RP, 5
μm, 6 mm, 250 mm) with Method 1 (flow rate: 1 mL/min; gradient: 15 min 5-95% B; 17 min
100% B; 20 min 100%-5% B); QC analysis was performed with Method 1. Radioactivity levels in
various samples were assessed using a Perkin Elmer Wizard II (Shelton, CT, USA) automated
gamma counter.

Cell Culture
Cells were cultivated in monolayer culture at 37 °C in a 5% CO2 humidified atmosphere,
following standard procedures. They were maintained in their respective growth medium (Roswell
Park Memorial Institute medium for JHU-LX22, and Eagle’s Minimum Essential Medium for
U251-MG and FaDu), containing 10% (v/v) fetal bovine serum and 1% penicillin/streptavidin
purchased from the culture medium preparation facility at MSKCC.

Mice
All in vivo experiments were performed with female athymic nude CrTac:NCr-Fo mice
were purchased from Taconic Laboratories (Hudson, NY) at age 6-8 weeks. Xenograft-bearing
mice were used to determine all pharmacokinetics, the binding/imaging properties, and the
treatment efficacy of the radiotherapeutic (ntotal = 20). During subcutaneous injections, mice were
anesthetized using 2% isoflurane gas in 2 L/min medical air. For intravenous injections, the lateral
tail vein was used. Mice were warmed with a heat lamp and placed in a restrainer, and the tail was
sterilized with alcohol pads before injection. JHU-LX22 cells were implanted subcutaneously (5
× 106 cells in 150 mL of 1:1 PBS/Matrigel [BD Biosciences]) into the right shoulder and allowed
to grow for approximately 2 weeks until the tumors reached about 8 mm in diameter (100 ± 8
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mm). All mouse experiments were performed in accordance with protocols approved by the
Institutional Animal Care and Use Committee of MSKCC and followed National Institutes of
Health guidelines for animal welfare.

Synthesis of 211At-PARPi
All reagents were purchased from Sigma-Aldrich except where noted. Astatine-211 was
produced on the Duke University CS-30 cyclotron via the 209Bi(α, 2n)211At reaction by
bombarding natural bismuth metal targets with 28 MeV α-particles, isolated from the target by dry
distillation, trapped in PEEK or PTFE tubing, and finally extracted with methanol as described
previously (Pozzi and Zalutsky 2007; Zalutsky et al. 2001). 211At-PARPi was synthesized from Nsuccinimidyl 3-(tri-n-butylstannyl)benzoate after electrophilic destannylation in the presence of
N-chlorosuccinimide in MeOH by 211At at 25 °C for 15 min, purified by cartridge and dried under
argon. Amide bond formation with 4-[[4-Fluoro-3-(piperazine-1-carbonyl)phenyl]methyl]-2Hphthalazin-1-one (300 μg, 0.9 μmol) was carried out similarly to previous synthetic procedures in
the presence of 1.1 eq of HBTU (375 μg, 0.99 μmol) in 20 μL DMSO, and 0.3 eq of DMAP
(100 μg, 0.31 μmol) in 20 μL DMSO, excess triethylamine in dry acetonitrile for 2 h at 65°C
(Jannetti et al. 2018; Pirovano et al. 2019). Product isolation was performed by HPLC on a C18
reverse-phase column and dried under argon. Coelution with nonradioactive 127I-PARPi reference
compound confirmed the identity of the radiotherapeutic.

Western Blot
PARP1 protein expression was measured in FaDu, U251-MG, and JHU-LX22 cell lysates
using Western blot analysis as described in previous papers (Kossatz et al. 2018). Briefly, proteins
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were isolated from cells and 20 µg of protein per sample were separated with SDS/PAGE gel
electrophoresis and transferred to a Nitrocellulose membrane. Proteins were detected using
antibodies specific for PARP1 (1:1,000, Invitrogen; PA5-16452) and β-actin (1:40,000; Cell
Signaling Technology; 3700) with a corresponding horseradish peroxidase (HRP) conjugated
secondary antibody (1:20,000, ab6721, Abcam, USA). Detection was performed using a
chemiluminescent substrate (Thermo Scientific #34077, Super Signal West Pico, USA). The bands
were visualized using an automated blot processing machine (Ewen-Parker X-Ray corporation,
New York, USA) with a light sensitive clear blue x-ray film (Thermo Scientific, 24x30 cm,
SB2324231, Belgium) with 30 seconds exposure time.

Uptake Assay
Uptake of 211At-PARPi was tested in vitro (3 replicates). 5×105 LX22 cells were plated 24h
prior to the experiment (n = 3). Media was changed and 1 h later 3.7 kBq of

211

At-PARPi were

added to the cells. To block uptake of our drug, cells were incubated with a 100-fold molar excess
of olaparib 1 h before adding 211At-PARPi. Media was removed, and cells were washed with PBS
and lysed (1 M NaOH). Lysates were collected, and uptake was determined by radioactivity on a
gamma counter.

Sub-cellular Fractionation
5×105 JHU-LX22 cells were plated 24h prior to the experiment (n = 3). Media was changed
and 1 h later 3.7 kBq of 211At-PARPi were added to the cells. Cells were collected and fractionated
using a Subcellular Protein Fractionation Kit from Thermo Scientific (78840) following the
manufacturer’s instructions. Uptake was determined by radioactivity on a gamma counter.
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Biodistribution
Mice were intravenously injected with 0.185 MBq of

211

At-PARPi four weeks after

xenograft. Biodistribution studies were performed in subcutaneous JHU-LX22 xenograft–bearing
athymic nude mice (n = 20, 4 randomized cohorts, 4 mice per cohort). Mice were intravenously
administered 211At-PARPi (0.185 MBq, 183 MBq/µmol in 100 µL, 30% PEG300 in 0.9% sterile
saline). Mice were sacrificed by CO2 asphyxiation at 1, 3, 6, and 18 h after injection and major
organs were collected, weighed, and counted in a Wizard II (Perkin Elmer) automated gammacounter. The 211At-PARPi uptake was expressed as a percentage of injected dose per gram (%ID/g)
using the following formula: [(activity in the target organ/g of tissue)/injected dose] × 100%.
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